Diversity-oriented synthesis based on the dppp-catalyzed mixed double-michael reactions of electron-deficient acetylenes and β-amino alcohols

Article abstract of DOI:10.3390/molecules16053802

In this study, we prepared oxizolidines through 1,3-bis(diphenylphosphino)- propane (DPPP)-catalyzed mixed double-Michael reactions of β-amino alcohols with electron-deficient acetylenes. These reactions are very suitable for the diversity-oriented parallel syntheses of oxizolidines because: (i) they are performed under mild metal-free conditions and (ii) the products are isolated without complicated work-up. To demonstrate the applicability of mixed double-Michael reactions for the preparation of five-membered-ring heterocycles, we prepared 60 distinct oxazolidines from five β-amino alcohols and 12 electron-deficient acetylenes. We synthesized 36 of these 60 oxazolidines in enantiomerically pure form from proteinogenic amino acid-derived β-amino alcohols.

Full text of DOI:10.3390/molecules16053802

Molecules 2011, 16, 3802-3825; doi:10.3390/molecules16053802
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Diversity-Oriented Synthesis Based on the DPPP-Catalyzed
Mixed Double-Michael Reactions of Electron-Deficient
Acetylenes and β-Amino Alcohols
Yi Chiao Fan and Ohyun Kwon *
Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA
* Author to whom correspondence should be addressed; E-Mail: ohyun@chem.ucla.edu.
Received: 6 April 2011; in revised form: 29 April 2011 / Accepted: 5 May 2011 /
Published: 5 May 2011
Abstract: In this study, we prepared oxizolidines through 1,3-bis(diphenylphosphino)-
propane (DPPP)–catalyzed mixed double-Michael reactions of β-amino alcohols with
electron-deficient acetylenes. These reactions are very suitable for the diversity-oriented
parallel syntheses of oxizolidines because: (i) they are performed under mild metal-free
conditions and (ii) the products are isolated without complicated work-up. To demonstrate the
applicability of mixed double-Michael reactions for the preparation of five-membered-ring
heterocycles, we prepared 60 distinct oxazolidines from five β-amino alcohols and 12
electron-deficient acetylenes. We synthesized 36 of these 60 oxazolidines in enantiomerically
pure form from proteinogenic amino acid–derived β-amino alcohols.
Keywords: phosphine catalysis; Michael reaction; oxazolidines; β-amino alcohols;
acetylenes
1. Introduction
Because small organic heterocyclic compounds are found in most pharmaceuticals and
agrochemicals and also in numerous natural products, additives, modifiers, and polymers [1,2], their
construction remains of great interest to the synthetic organic chemistry community. In particular, the
preparation of libraries of heterocyclic compounds through parallel combinatorial synthesis [3,4] or
branched diversity-oriented synthesis [5-7] would be an attractive approach toward identifying
biologically active small organic molecules [8-10]. Simple, robust, and metal-free methods for

Molecules 2011, 16
3803
synthesizing small molecules are especially attractive if these compounds are to be used for biological
testing. Furthermore, reactions involving organocatalysis are becoming increasingly desirable in terms
of their low environmental impact. From these considerations, phosphine-catalyzed annulation has
served as an ideal format for synthesizing diverse groups of heterocyclic small molecules with high
efficiency and minimal impact on the environment [11-29]. In particular, 1,3-bis(diphenylphosphino)-
propane (DPPP)–catalyzed double Michael addition has proved to be an atom-economical platform for
preparing ten unique heterocyclic compounds [30,31].
A little over three decades ago, White and Baizer reported the first phosphine-catalyzed Michael
additions of benzyl alcohol to activated olefins [32]. Only in the last two decades, however, did other
synthetic research groups start studying Michael additions using nucleophilic phosphine catalysts and
activated acetylenes. Inanaga demonstrated the first Michael additions of benzyl alcohol to activated
acetylenes in the presence of nucleophilic phosphine catalysts [33]. When acetylenes are used as
Michael acceptors, the Michael products possess one remaining degree of unsaturation, thereby
enabling further incorporation of nucleophiles.
Capitalizing on the possibility of performing two consecutive Michael additions to activated
acetylenes, Grossman elegantly demonstrated the double-Michael additions of carbon pro-nucleophiles
to generate functionalized cyclohexanes under the influence of phosphine catalysts and bases [34,35].
Subsequently, Yavari employed catechol—an oxygen di-nucleophile—as the Michael donor [36];
although the yield of the resulting 1,3-benzodioxole was low (20%, isolated), he confirmed that
heteroatom double-Michael addition under phosphine catalysis was possible [37]. Nevertheless, to this
day, few heterocyclic compounds have been generated using double-Michael additions.
To overcome poor efficiency and the inability to incorporate other heteroatoms such as nitrogen and
sulfur, in the phosphine-catalyzed double-Michael reactions, we set out to develop a route to generate
various heterocyclic compounds under general and robust phosphine catalysis conditions. By
employing DPPP as the catalyst, we have synthesized functionalized oxazolidines, thiazolidines,
and pyrrolidines in high efficiency (Scheme 1) [30]. By employing dinucleophiles tethered
through aromatic rings, we have obtained indolines, dihydropyrrolopyridines, benzimidazolines,
tetrahydroquinolines, tetrahydroisoquinolines, dihydrobenzo-1,4-oxazines, and dihydrobenzo-3,1-
oxazines using our developed mixed double-Michael strategy [31].
Scheme 1. DPPP-Catalyzed Mixed Double-Michael Reactions.
Focusing on oxazolidines, here we report the synthesis of a library of 60 distinct oxazolidines
through our mixed double-Michael strategy. Based on previously reported mixed double-Michael
reactions [30,31], we knew that oxazolidines could be prepared from amino acid–derived
pro-nucleophiles and electron-deficient acetylenes using DPPP as the catalyst. With such precedents in
mind, here we expanded the reaction scope of the mixed double-Michael reaction to incorporate

Molecules 2011, 16
3804
various oxygen-and-nitrogen-containing pro-nucleophiles and electron-deficient acetylenes. Under the
reported conditions, we obtained the various oxazolidine derivatives rapidly and with high efficiency,
enabling their future application in biological assays.
Oxazolidine, a five-membered-ring heterocycle containing both oxygen and nitrogen atoms, appears
in many natural products that possess important biological activities. Quinocarcin and tetrazomine are
two examples of the many naturally occurring oxazolidine-containing molecules displaying useful
pharmacological activities (e.g., antitumor, cytotoxic, anti-inflammatory, and analgesic properties) [38,39].
Furthermore, enantiomerically pure oxazolidines can be used as chiral auxiliaries to induce asymmetry
in organic reactions [40-45].
Figure 1. Oxazolidine-Containing Natural Products.
2. Results and Discussion
2.1. Preparation of Pro-Nucleophiles
The β-amino alcohol pro-nucleophiles that we used in the mixed double-Michael reactions were
derived from natural L-amino acids and racemic cyclohexene oxide. We prepared the pro-nucleophiles
derived from L-leucine, L-alanine, L-phenylalanine, and L-serine efficiently according to protocols
described by Moberg and Craig [46]; first, we protected the amino groups of L-leucine, L-alanine,
L-phenylalanine, and L-serine with p-toluenesulfonyl (tosyl) chloride and then we reduced their
carboxylic acid units using lithium aluminum hydride [47,48]. We prepared the 2-aminocyclohexanol–
derived pro-nucleophile 1e from racemic cyclohexene oxide in three steps: opening of the epoxide
with sodium azide, reduction of the azido group with palladium on charcoal [49,50], and then
protection of the amino group with tosyl chloride [51].
Scheme 2. Amino-Alcohol Pro-Nucleophiles.
2.2. Preparation of Electron-Deficient Acetylenes
Table 1 lists the electron-deficient acetylenes that we prepared from corresponding aldehydes.
Although the syntheses of the acetylenes 2a, 2c, and 2e have been reported previously, the acetylenes
2b, 2d, and 2f were unknown. Employing the protocol established by Oyelere and Calieno [52,53], we
obtained each of these propargyl ketones in good yield after: (i) treating the pertinent aldehyde with

Molecules 2011, 16
3805
ethynylmagnesium bromide at 0 °C, slowly warming to ambient temperature, and then working-up the
mixture after 4 h and (ii) oxidizing the resulting propargyl alcohol, without further purification, using
Jones reagent.
Table 1. Synthesis of Electron-Deficient Acetylenes.
Entry
R2
Ph
Acetylene
Yield (%)
1
2
3
4
5
6
2a
2b
2c
2d
2e
2f
83
76
89
76
67
75
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
2.3. Synthesis of an Oxazolidine Library
With all the pro-nucleophiles and acetylenes at hand, we rapidly synthesized the desired chemical
library of 60 distinct oxazolidines using DPPP as the catalyst (Tables 2–4). The oxazolidine library
contained a diverse array of functional groups and provided several potential probes for examining
various biological mechanisms.
The pro-nucleophiles 1a–c generated their desired oxazolidines in good to high yields, revealing
that the reactions had good tolerance for various alkyl groups on the pro-nucleophiles (Table 2, entries
1–33). In contrast, the pro-nucleophile 1d provided its products in low to moderate yields, suggesting
that the additional free hydroxyl functionality impeded the mixed double-Michael reactions (Table 2,
entries 34–44). The yields of oxazolidines were even lower when we used 1e as the pro-nucleophile
(Table 3), presumably because of steric hindrance about the secondary alcohol pro-nucleophile.
We tested various activated acetylenes to evaluate their reactivities in the mixed double-Michael
reactions. Alkyl propiolates afforded their desired oxazolidines in good to high yields (Table 1, entries
1–3, 12–14, 23–25, and 34–36). In contrast, the use of phenyl propiolate provided drastically lower
yields of its oxazolidines (Table 1, entries 4, 15, 26, and 37), possibly because it was prone to
hydrolysis under the reaction conditions.
Butynone and aromatic propargyl ketones afforded their oxazolidines in good yields from a range of
pro-nucleophiles. Halogens and electron-donating groups on the benzene rings of the aromatic
propargyl ketones were compatible with the mixed double-Michael reactions. Naphthyl and 2-thienyl
groups were also tolerated in the reaction. Aside from using carbonyl moieties as electron withdrawing
groups, we also employed an aromatic sulfone unit to activate the acetylene; tosyl acetylene provided
its oxazolidines in good yields from the mixed double-Michael reactions (Table 4).

Molecules 2011, 16
3806
Table 2. Synthesis of Trisubstituted Oxazolidines.
Entry
1
R1
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me
Bn
Bn
Bn
Bn
Bn
Bn
Bn
Bn
Bn
Bn
R2
OMe
OEt
OBn
OPh
Oxazolidine
(2S, 4S)-3a
(2S, 4S)-3b
(2S, 4S)-3c
(2S, 4S)-3d
(2S, 4S)-3e
(2S, 4S)-3f
(2S, 4S)-3g
(2S, 4S)-3h
(2S, 4S)-3i
(2S, 4S)-3j
(2S, 4S)-3k
(2S, 4S)-4a
(2S, 4S)-4b
(2S, 4S)-4c
(2S, 4S)-4d
(2S, 4S)-4e
(2S, 4S)-4f
(2S, 4S)-4g
(2S, 4S)-4h
(2S, 4S)-4i
(2S, 4S)-4j
(2S, 4S)-4k
(2S, 4S)-5a
(2S, 4S)-5b
(2S, 4S)-5c
(2S, 4S)-5d
(2S, 4S)-5e
(2S, 4S)-5f
(2S, 4S)-5g
(2S, 4S)-5h
(2S, 4S)-5i
(2S, 4S)-5j
(2S, 4S)-5k
(±)-6a
Yield (%)
59
75
63
22
53
55
28
58
63
70
37
68
68
64
14
68
57
41
90
27
33
25
66
81
76
5
45
71
30
98
51
96
41
38
50
37
8
2
3
4
5
6
7
8
9
Me
Ph
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
OMe
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
OEt
OBn
OPh
Me
Ph
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
OMe
OEt
OBn
OPh
Me
Ph
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
OMe
Bn
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
CH2OH
OEt
OBn
OPh
Me
(±)-6b
(±)-6c
(±)-6d
(±)-6e
(±)-6f
(±)-6g
(±)-6h
(±)-6i
29
23
12
38
23
24
58
Ph
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
(±)-6j
(±)-6k

Molecules 2011, 16
3807
Table 3. Synthesis of Octahydrobenzoxazolidines.
Entry
R
OMe
Oxazolidine
(±)-7a
(±)-7b
(±)-7c
(±)-7d
(±)-7e
(±)-7f
Yield (%)
1
2
15
37
19
13
33
32
18
93
27
33
25
OEt
3
OBn
4
OPh
5
Me
6
Ph
7
m,p-Cl2C6H3
m,p-(CH3O)2C6H3
p-FC6H4
1-naphthyl
2-thienyl
(±)-7g
(±)-7h
(±)-7i
8
9
10
11
(±)-7j
(±)-7k
Table 4. Tosyl Acetylene as Mixed Double-Michael Acceptor.
Entry
Pro-Nucleophile
Oxazolidine
Yield (%)
1
(2S, 4S)-8a
30
2
3
4
(2S, 4S)-8b
(2S, 4S)-8c
(±)-8d
68
65
81
5
37
(±)-8e
3. Experimental
3.1. General
All reactions were performed in flamed-dried or oven-dried round-bottom flasks, Schlenk flasks, or
two-neck flasks. A glass water condenser, fitted with a rubber septum, was attached to each flask. All
reactions were performed under a positive pressure of argon. A syringe pump and stainless-steel
needles were used to inject the acetylene derivatives into the refluxing reaction mixtures. Reactions
were monitored through thin-layer chromatography (TLC) on 0.25-mm SiliCycle silica gel plates.
Plates were visualized under UV light or through p-anisaldehyde or potassium permanganate staining

Molecules 2011, 16
3808
followed by heating (<1 min) with a heat gun. Flash column chromatography (FCC) was performed
using SiliCycle Silica-P Flash silica gel (60 Å pore size, 40–63 µm). Organic solutions were
concentrated using rotary evaporators.
3.2. Materials and Reagents
Reagents were used as received from commercial sources. Methyl propiolate and ethyl propiolate
were purchased from TCI America. Tosyl acetylene and 3-butyn-2-one were purchased from Aldrich.
Acetonitrile and dichloromethane were distilled from calcium hydride under a positive pressure of
argon. Tetrahydrofuran was distilled from sodium and benzophenone under a positive pressure
of argon.
3.3. Instrumentation
IR spectra were recorded using a Thermo Nicolet Avatar 370 FT-IR spectrometer. NMR spectra
were recorded using Bruker ARX-400 instrument, calibrated to signals from the solvent as an internal
reference [7.26 (residual CHCl3) and 77.00 (CDCl3) ppm for ¹H- and ¹³C-NMR spectra, respectively].
1
Data for H NMR spectra are reported as follows: chemical shift (δ, ppm), multiplicity, coupling
constant (Hz), and integration. Data for 13C-NMR spectra are reported in terms of chemical shift. The
following abbreviations are used to denote the multiplicities: s = singlet; d = doublet; t = triplet;
q = quartet; m = multiplet. Mass spectra of the samples were recorded using a Waters LCT Premier XE
time-of-flight instrument controlled by MassLynx 4.1 software. Samples were infused through direct
loop injection from a Waters Acquity UPLC into the multi-mode ionization source. The lock mass
standard for accurate mass determination was leucine enkephalin (Sigma L9133). An Agilent
Technologies 5975 inert XL mass-selective detector GCMS was also used.
3.4. Synthesis of Electron-Deficient Acetylenes
1-Phenylprop-2-yn-1-one (2a) was prepared in 83% yield using the protocol described by Oyelere and
Calieno [52,53]. Spectral data matched those reported in the literature [53].
1-(3,4-Dichlorophenyl)prop-2-yn-1-one (2b) was prepared in 76% yield using the protocol described
by Oyelere and Calieno [52,53]; yellow solid; IR (CH2Cl2) νmax 3219.3, 2093.63, 1639.0, 1579.0,
1
1232.4, 750.1 cm–1; H-NMR (400 MHz, CDCl3) δ 8.23 (s, 1H), 7.97–8.00 (m, 1H), 7.58–7.61
13
(m, 1H), 3.51 (s, 1H); C-NMR (100 MHz, CDCl3) δ 174.9, 139.4, 135.7, 133.5, 130.9, 128.4, 81.9,
79.5, 77.2; GCMS (EI+) calcd for [C9H4Cl2O]: m/z 199.0, found 199.0.
1-(3,4-Dimethoxyphenyl)prop-2-yn-1-one (2c): 89% yield; spectral data matched those reported in the
literature [54].
1-(4-Fluorophenyl)prop-2-yn-1-one (2d) was prepared in 76% yield using the protocol described by
Oyelere and Calieno [52,53]; brown solid; IR (CH2Cl2) νmax 3211.7, 2093.45, 1651.4, 1598.3, 1255.5,
1155.4, 754.6 cm–1; 1H-NMR (400 MHz, CDCl3) δ 8.20 (d, J = 4.0 Hz, 2H), 7.18 (d, J = 4.0 Hz, 2H),

Molecules 2011, 16
3809
3.45 (s, 1H); 13C-NMR (100 MHz, CDCl3) δ 175.7, 168.0, 165.4, 132.5, 116.1, 115.9, 81.0, 80.0, 77.2;
GCMS (EI+) calcd for [C9H5FO]: m/z 148.1, found 148.1.
1-(Naphthalen-1-yl)prop-2-yn-1-one (2e): 67% yield; spectral data matched those reported in the
literature [55].
1-(Thien-2-yl)prop-2-yn-1-one (2f) was prepared in 75% yield using the protocol described by Oyelere
and Calieno [52,53]; brown solid; IR (CH2Cl2) νmax 3239.2, 2093.3, 1619.1, 1409.8, 1279.2,
734.4 cm–1; 1H-NMR (400 MHz, CDCl3) δ 7.96 (d, J = 4.0 Hz, 1H), 7.74 (d, J = 4.0 Hz, 1H), 7.16 (t,
J = 4.0 Hz, 1H), 3.37 (s, 1H); 13C-NMR (100 MHz, CDCl3) δ 169.1, 144.1, 136.2, 129.1, 128.5, 79.4,
77.3; GCMS (EI+) calcd for [C7H4OS]: m/z 136.2, found 136.1.
Phenyl propiolate was prepared in 90% yield according to the protocol described by Ramachandran;
spectral data matched those reported in the literature [56].
Benzyl propiolate was prepared in 90% yield according to the protocol described by Ramachandran;
spectral data matched those reported in the literature [57].
3.5. General Procedure for Mixed Double-Michael Reaction
The N-tosylamido alcohol pro-nucleophile (1 mmol), DPPP (84.2 mg, 0.2 mmol), and CH3CN
(5 mL) were placed in a dried two-neck round-bottom flask (25 mL) equipped with a magnetic stirrer
bar. The mixture was brought to reflux in an oil bath (external temperature: 90 °C). A solution of the
electron-deficient acetylene (1.2 mmol) in CH3CN (1 mL) was added into the flask over 1 h using a
syringe pump. [In the case of ethynyl p-tolyl sulfone, the acetylene (1.2 mmol) was added to the flask
over 2 h via syringe pump.] The reaction mixture was stirred overnight under reflux, under a positive
pressure of argon, monitoring with TLC (20% EtOAc in hexanes). The resulting reaction mixture
was concentrated in vacuo and purified by FCC on silica gel (20% EtOAc in hexanes) to yield the
cyclized product.
Methyl 2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]acetate (3a). 59% yield; white solid; IR
1
(CH2Cl2) νmax 2960.7, 1741.9, 1598.1, 1351.2, 1164.7 cm–1; H-NMR (400 MHz, CDCl3) δ 7.68 (d,
J = 8.4 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.23 (dd, J = 8.8, 3.2 Hz, 1H), 3.69 (dd, J = 9.2, 2.4 Hz, 1H),
3.64 (s, 3H), 3.35 (ddd, J = 7.9, 6.1, 2.1 Hz, 1H), 3.00–3.07 (m, 2H), 2.62 (dd, J = 15.8, 8.6 Hz, 1H),
13
2.36 (s, 3H), 1.78–1.86 (m, 1H), 0.95 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); C-NMR (100
MHz, CDCl3) δ 169.9, 144.4, 133.7, 130.0, 127.9, 88.8, 67.8, 64.9, 51.8, 41.8, 31.3, 21.5, 19.5, 18.4;
HRMS (ESI+) calcd for [C16H23NO5S]+: m/z 342.1370, found 342.1364.
Ethyl 2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]acetate (3b). 75% yield; yellow oil; IR (CH2Cl2)
1
νmax 2964.4, 1736.0, 1598.0, 1351.6, 1165.3 cm–1; H-NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.4 Hz,
2H), 7.25 (d, J = 8.0 Hz, 2H), 5.21 (dd, J = 8.8, 3.2 Hz, 1H), 4.07 (q, J = 7.2 Hz, 2H), 3.66 (dd, J = 9.0,
2.2 Hz, 1H), 3.32 (ddd, J = 7.7, 6.1, 1.9 Hz, 1H), 2.96–3.04 (m, 2H), 2.58 (dd, J = 15.8, 8.6 Hz, 1H),

Molecules 2011, 16
3810
2.32 (s, 3H), 1.75–1.84 (m, 1H), 1.17 (t, J = 7.0 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz,
13
3H); C-NMR (100 MHz, CDCl3) δ 169.5, 144.3, 133.7, 130.0, 127.9, 88.9, 67.8, 64.8, 60.7, 42.0,
31.3, 21.4, 19.5, 18.4, 14.1; HRMS (ESI+) calcd for [C17H25NO5S]+: m/z 356.1526, found 356.1518.
Benzyl 2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]acetate (3c). 63% yield; yellow oil; IR (CH2Cl2)
1
νmax 3031.4, 2962.6, 1738.7, 1597.8, 1351.2, 1164.7 cm–1; H-NMR (400 MHz, CDCl3) δ 7.73 (d,
J = 8.0 Hz, 2H), 7.30–7.36 (m, 7H), 5.35 (dd, J = 8.6, 3.0 Hz, 1H), 5.15 (s, 2H), 3.75 (dd, J = 9.0,
2.2 Hz, 1H), 3.42 (ddd, J = 7.7, 5.9, 2.1 Hz, 1H), 3.09–3.17 (m, 2H), 2.75 (dd, J = 15.8, 8.6 Hz, 1H),
2.40 (s, 3H), 1.84–1.91 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C-NMR
(100 MHz, CDCl3) δ 169.5, 144.4, 135.7, 133.8, 130.1, 130.0, 128.6, 128.3, 128.0, 88.9, 67.9, 66.6,
65.0, 42.0, 31.4, 21.6, 19.6, 18.5. HRMS (ESI+) calcd for [C22H27NO5S]+: m/z 418.1683, found
418.1671.
Phenyl 2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]acetate (3d). 22% yield; yellow oil; IR (CH2Cl2)
νmax 3065.2, 2963.8, 1758.9, 1594.3, 1351.3, 1306.6, 1164.5 cm–1; 1H-NMR (400 MHz, CDCl3) δ 7.77
(d, J = 8.4 Hz, 2H), 7.34–7.37 (m, 4H), 7.21–7.25 (m, 1H), 7.12 (d, J = 1.2 Hz, 2H), 5.42 (dd, J = 8.2,
3.4 Hz, 1H), 3.82 (dd, J = 9.2, 2.4 Hz, 1H), 3.44 (ddd, J = 7.8, 6.0, 2.0 Hz, 1H), 3.34 (dd, J = 15.8,
3.4 Hz, 1H), 3.16 (dd, J = 9.2, 6.4 Hz, 1H), 2.93 (dd, J = 15.8, 8.2 Hz, 1H), 2.43 (s, 3H), 1.93–1.99 (m,
13
1H), 1.05 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 168.2, 150.5,
144.5, 133.7, 130.1 , 129.4, 128.1, 126.0, 121.6, 88.9, 67.9, 65.0, 42.2, 31.4, 21.6, 19.6, 18.5; HRMS
(ESI+) calcd for [C21H25NO5S]+: m/z 404.1526, found 404.1510.
1-[(2S,4S)-4-Isopropyl-3-tosyloxazolidin-2-yl]propan-2-one (3e). 53% yield; light yellow oil; IR
1
(CH2Cl2) νmax 2963.3, 1719.4, 1597.9, 1348.5, 1164.1 cm–1; H-NMR (400 MHz, CDCl3) δ 7.65 (d,
J = 8.4 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 5.19 (dd, J = 8.4, 2.4 Hz, 1H), 3.66 (dd, J = 9.0, 1.8 Hz, 1H),
3.31 (ddd, J = 7.6, 6.0, 1.6 Hz, 1H), 3.12 (dd, J = 17.0, 2.6 Hz, 1H), 2.99 (dd, J = 9.0, 6.2 Hz, 1H),
2.78 (dd, J = 16.8, 8.4 Hz, 1H), 2.35 (s, 3H), 2.13, (s, 3H), 1.76–1.85 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H),
0.86 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 205.1, 144.3, 133.6, 130.0, 127.9, 88.3, 67,8,
64.7, 50.3, 31.4, 30.7, 21.5, 19.5, 18.4; HRMS (ESI+) calcd for [C16H23NO4S]+: m/z 326.1421, found
326.1416.
2-[(2S,4S)-4-Isopropyl-3-tosyloxazolidin-2-yl]-1-phenylethanone (3f). 55% yield; yellow solid; IR
1
(CH2Cl2) νmax 3062.5, 2963.3, 1686.1, 1597.3, 1349.4, 1164.5 cm–1; H-NMR (400 MHz, CDCl3) δ
7.95 (d, J = 6.8 Hz, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.41–7.53 (m, 3H), 7.31 (d, J = 12.0 Hz, 2H), 5.45
(dd, J = 8.8, 2.0 Hz, 1H), 3.74 (dq, J = 12.8, 2.0 Hz, 2H), 3.35–3.43 (m, 2H), 3.06 (dd, J = 8.8, 6.0 Hz,
13
1H), 2.37 (s, 3H), 1.86–1.95 (m, 1H), 1.02 (d, J = 7.2 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H); C-NMR
(100 MHz, CDCl3) δ 196.6, 144.4, 136.6, 133.6, 133.5, 130.1, 128.7, 128.2, 128.0, 89.0, 67.9, 64.8,
45.9, 31.5, 21.5, 19.6, 18.5; HRMS (ESI+) calcd for [C21H25NO4S]+: m/z 388.1577, found 388.1568.
1-(3,4-Dichlorophenyl)-2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]ethanone (3g). 28% yield;
1
yellow solid; IR (CH2Cl2) νmax 3064.1, 2963.2, 1691.3, 1584.2, 1350.0, 1164.8 cm–1; H-NMR
(400 MHz, CDCl3) δ 8.02 (d, J = 2.0 Hz, 2H), 7.78 (dd, J = 8.4, 2.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H),

Molecules 2011, 16
3811
7.53 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 5.38 (dd, J = 8.4, 2.0 Hz, 1H), 3.76 (dd, J = 9.2,
1.6 Hz, 1H), 3.71 (dd, J = 16.6, 2.2 Hz, 1H), 3.39 (ddd, J = 7.6, 6.0, 1.6 Hz, 1H), 3.06 (dd, J = 9.0,
6.2 Hz, 1H), 3.06 (dd, J = 9.0, 6.2 Hz, 1H), 2.41 (s, 3H), 1.85–1.92 (m, 1H), 1.02 (d, J = 7.2 Hz, 3H),
13
0.94 (d, J = 6.8 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 194.5, 144.5, 138.0, 136.1, 133.5, 133.4,
130.8, 130.2, 130.1, 128.0, 127.4, 88.7, 67.9, 64.8, 46.0, 31.5, 21.6, 19.6, 18.5; HRMS (ESI+) calcd for
[C21H23Cl2NO4S]+: m/z 456.0798, found 456.0756.
1-(3,4-Dimethoxyphenyl)-2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]ethanone (3h). 58% yield;
1
yellow oil; IR (CH2Cl2) νmax 3068.2, 2962.9, 1673.5, 1595.7, 1347.3, 1164.0 cm–1; H-NMR
(400 MHz, CDCl3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.54 (dd, J = 8.4, 2.0 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H),
5.36 (dd, J = 8.8, 2.0 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.61–3.70 (m, 2H), 3.33 (ddd, J = 7.5, 6.1,
1.7 Hz, 1H), 3.24 (dd, J = 16.4, 8.8 Hz, 1H), 2.32 (s, 3H), 1.80–1.89 (m, 1H), 0.95 (d, J = 7.2 Hz, 3H),
13
0.87 (d, J = 6.8 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 195.1, 153.6, 149.0, 144.3, 133.6, 130.0,
129.8, 128.0, 123.2, 110.2, 89.2, 67.8, 64.7, 56.0, 55.9, 45.4, 31.4, 21.4, 19.6, 18.4; HRMS (ESI+)
calcd for [C23H29NO6S]+: m/z 448.1788, found 448.1790.
1-(4-Fluorophenyl)-2-[(2S,4S)-4-isopropyl-3-tosyloxazolidin-2-yl]ethanone (3i). 63% yield; brown oil;
1
IR (CH2Cl2) νmax 3068.8, 2963.8, 1686.0, 1597.3, 1349.6, 1164.7 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.97 (t, J = 6.8 Hz, 2H), 7.70 (d, J = 7.6 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.09 (t, J = 8.0 Hz, 2H),
5.40 (dd, J = 8.6, 1.8 Hz, 1H), 3.67–3.74 (m, 2H), 3.29–3.40 (m, 2H), 3.04 (dd, J = 8.8, 6.4 Hz, 1H),
2.37 (s, 3H), 1.84–1.92 (m, 1H), 1.00 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C-NMR
(100 MHz, CDCl3) δ 195.0, 167.2, 164.6, 144.4, 133.6, 133.1, 131.0, 130.1, 130.0, 128.0, 115.8, 115.6,
89.0, 67.9, 64.8, 45.8, 31.5, 21.5, 19.6, 18.5; HRMS (ESI+) calcd for [C21H24FNO4S]+: m/z 406.1483,
found 406.1477.
2-[(2S,4S)-4-Isopropyl-3-tosyloxazolidin-2-yl]-1-(naphth-1-yl)ethanone (3j). 70% yield; yellow oil; IR
1
(CH2Cl2) νmax 3051.1, 2963.2, 1680.3, 1595.9, 1348.4, 1164.0 cm–1; H-NMR (400 MHz, CDCl3)
δ 8.72 (d, J = 8.4 Hz, 1H), 7.96–7.98 (m, 2H), 7.84 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 2H),
7.48–7.59 (m, 3H), 7.27 (d, J = 11.6 Hz, 2H), 5.55 (dd, J = 8.8, 2.4 Hz, 1H), 3.92 (dd, J = 16.6, 2.2 Hz,
1H), 3.79 (dd, J = 9.0, 1.8 Hz, 1H), 3.45 (ddd, J = 13.5, 6.7, 4.5 Hz, 2H), 3.10 (dd, J = 9.0, 6.2 Hz,
13
1H), 2.37 (s, 3H), 1.90–1.98 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.4 Hz, 3H); C-NMR
(100 MHz, CDCl3) δ 200.3, 144.4, 135.0, 134.0, 133.7, 133.3, 130.2, 130.1, 128.5, 128.1, 126.6, 126.0,
124.4, 89.4, 68.0, 64.9, 49.1, 31.6, 21.5, 19.7, 18.6; HRMS (ESI+) calcd for [C25H27NO4S]+: m/z
438.1734, found 438.1730.
2-[(2S,4S)-4-Isopropyl-3-tosyloxazolidin-2-yl]-1-(thien-2-yl)ethanone (3k). 37% yield; brown solid;
1
IR (CH2Cl2) νmax 3102.5, 2963.1, 1660.1, 1597.6, 1348.8, 1164.0 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.77 (d, J = 1.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.64 (dd, J = 5.0, 1.0 Hz, 1H), 7.32 (d, J = 8.0 Hz,
2H), 7.12 (dd, J = 5.0, 3.8 Hz, 1H), 5.39 (dd, J = 8.4, 2.4 Hz, 1H), 3.75 (dd, J = 9.2, 2.0 Hz, 1H), 3.64
(dd, J = 15.8, 2.2 Hz, 1H), 3.39 (ddd, J = 7.6, 6.0, 1.8 Hz, 1H), 3.30 (dd, J = 16.0, 8.4 Hz, 1H), 3.06
(dd, J = 8.8, 6.0 Hz, 1H), 2.40 (s, 3H), 1.86–1.95 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz,
13
3H); C-NMR (100 MHz, CDCl3) δ 189.1, 144.4, 144.1, 134.4, 133.6, 132.8, 130.1, 128.3, 128.0,

Molecules 2011, 16
3812
89.0, 67.9, 64.8, 46.5, 31.5, 21.6, 19.6, 18.5; HRMS (ESI+) calcd for [C19H23NO4S2]+: m/z 394.1141,
found 394.1152.
Methyl 2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]acetate (4a). 68% yield; white solid; IR (CH2Cl2)
1
νmax 2983.0, 1739.9, 1598.2, 1350.8, 1164.8 cm–1; H-NMR (400 MHz, CDCl3) δ 7.69 (d, J = 1.6 Hz,
2H), 7.30 (d, J = 8.0 Hz, 2H), 5.29 (dd, J = 8.8, 2.8 Hz, 1H), 3.65–3.70 (m, 4H), 3.52 (dd, J = 9.0,
4.2 Hz, 1H), 3.41 (dd, J = 8.8, 6.0 Hz, 1H), 3.04 (dd, J = 16.0, 3.2 Hz, 1H), 2.69 (dd, J = 15.6, 8.8 Hz,
1H), 2.38 (s, 3H), 1.29 (d, J = 6.4 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 169.9, 144.4, 133.6, 130.0,
127.8, 127.1, 88.9, 71.8, 55.1, 51.9, 51.8, 42.1, 21.5, 20.9; HRMS (ESI+) calcd for [C14H19NO5S]+:
m/z 314.1057, found 314.1050.
Ethyl 2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]acetate (4b). 68% yield; white solid; IR (CH2Cl2)
1
νmax 2982.7, 1736.4, 1598.3, 1351.1, 1164.9 cm–1; H-NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.4 Hz,
2H), 7.26 (d, J = 8.0 Hz, 2H), 5.25 (dd, J = 8.6, 3.0 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 3.65 (ddd,
J = 8.3, 4.3, 2.1 Hz, 1H), 3.48 (dd, J = 9.0, 4.2 Hz, 1H), 3.37 (dd, J = 8.8, 6.0 Hz, 1H), 2.98 (dd,
J = 15.8, 3.0 Hz, 1H), 2.63 (dd, J = 15.6. 8.8 Hz, 1H), 2.33 (s, 3H), 1.24 (d, J = 6.4 Hz, 3H), 1.18 (t,
13
J = 7.2 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 169.4, 144.3, 133.6, 130.0, 127.8, 127.1, 88.9, 71.8,
60.7, 55.0, 42.2, 21.4, 20.8, 14.1; HRMS (ESI+) calcd for [C15H21NO5S]+: m/z 328.1213, found
328.1207.
Benzyl 2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]acetate (4c). 64% yield; yellow oil; IR (CH2Cl2)
1
νmax 3064.8, 2979.9, 1738.1, 1598.1, 1351.1, 1165.1 cm–1; H-NMR (400 MHz, CDCl3) δ 7.73 (d,
J = 8.4 Hz, 2H), 7.28–7.36 (m, 6H), 5.38 (dd, J = 8.6, 3.0 Hz, 1H), 5.16 (s, 2H), 3.73 (ddd, J = 8.5, 4.1,
2.1 Hz, 1H), 3.55 (dd, J = 8.8, 4.0 Hz, 1H), 3.46 (dd, J = 9.0, 6.2 Hz, 1H), 3.14 (dd, J = 15.8, 3.0 Hz,
13
1H), 2.79 (dd, J = 15.8, 8.6 Hz, 1H), 2.41 (s, 3H), 1.32 (d, J = 6.4 Hz, 3H); C-NMR (100 MHz,
CDCl3) δ 169.4, 144.4, 135.7, 133.6, 130.1, 130.0, 128.6, 128.5, 128.3, 127.9, 127.2, 89.0, 71.9, 66.6,
55.2, 42.3, 21.6, 20.9; HRMS (ESI+) calcd for [C20H23NO5S]+: m/z 390.1317, found 390.1346.
Phenyl 2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]acetate (4d). 14% yield; yellow oil; IR (CH2Cl2)
1
νmax 3068.2, 2980.3, 1758.4, 1593.7, 1350.8, 1164.3 cm–1; H-NMR (400 MHz, CDCl3) δ 7.77 (d,
J = 8.4 Hz, 2H), 7.34–7.40 (m, 5H), 7.23–7.25 (m, 1H), 7.12 (d, J = 1.2 Hz, 2H), 5.45 (dd, J = 8.2,
3.4 Hz, 1H), 3.76 (ddd, J = 8.4, 4.4, 2.0 Hz, 1H), 3.64 (dd, J = 8.8, 4.0 Hz, 1H), 3.52 (dd, J = 8.8,
6.4 Hz, 1H), 3.34 (dd, J = 15.8, 3.4 Hz, 1H), 2.99 (dd, J = 15.8, 8.2 Hz, 1H), 2.44 (s, 3H), 1.39 (d,
J = 6.4 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 168.0, 150.5, 144.4, 133.6, 130.1, 129.4, 129.1, 127.9,
126.0, 121.6, 88.9, 72.0, 55.2, 42.5, 21.6, 21.0; HRMS (ESI+) calcd for [C19H21NO5S]+: m/z 376.1213,
found 376.1204.
1-[(2S,4S)-4-Methyl-3-tosyloxazolidin-2-yl]propan-2-one (4e). 68% yield; yellow oil; IR (CH2Cl2) νmax
2980.2, 1715.8, 1598.2, 1348.8, 1164.6 cm–1; 1H-NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.4 Hz, 2H),
7.28 (d, J = 8.0 Hz, 2H), 5.23 (dd, J = 8.4, 2.4 Hz, 1H), 3.65 (ddd, J = 7.8, 4.6, 1.8 Hz, 1H), 3.47 (dd,
J = 8.8, 3.6 Hz, 1H), 3.32 (dd, J = 9.0, 6.2 Hz, 1H), 3.11 (dd, J = 16.6, 2.6 Hz, 1H), 2.84 (dd, J = 16.4.
8.4 Hz, 1H), 2.36 (s, 3H), 2.14 (s, 3H), 1.26 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 205.1,

Molecules 2011, 16
3813
144.3, 133.5, 130.0, 127.8, 126.9, 88.4, 71.8, 54.9, 50.6, 30.8, 21.5, 21.0; HRMS (ESI+) calcd for
[C14H19NO4S]+: m/z 298.1108, found 298.1128.
2-[(2S,4S)-4-Methyl-3-tosyloxazolidin-2-yl]-1-phenylethanone (4f). 57% yield; white solid; IR
1
(CH2Cl2) νmax 3062.3, 2980.2, 1686.7, 1597.3, 1348.9, 1164.5 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.97 (d, J = 7.2 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.53–7.74 (m, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.31
(d, J = 8.0 Hz, 2H), 5.50 (dd, J = 8.8, 2.0 Hz, 1H), 3.71–3.75 (m, 2H), 3.55 (dd, J = 8.8, 3.6 Hz, 1H),
3.37–3.45 (m, 2H), 2.39 (s, 3H), 1.35 (d, J = 6.4 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 196.6, 144.4,
136.6, 133.5, 130.1, 130.0, 129.6, 128.7, 128.3, 127.9, 89.0, 71.9, 55.0, 46.3, 21.6, 21.1; HRMS (ESI+)
calcd for [C19H21NO4S]+: m/z 360.1264, found 360.1260.
1-(3,4-Dichlorophenyl)-2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]ethanone (4g). 41% yield; brown
1
oil; IR (CH2Cl2) νmax 3065.8, 2980.5, 1692.7, 1584.3, 1349.3, 1164.8 cm–1; H-NMR (400 MHz,
CDCl3) δ 8.03 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 8.4, 2.0 Hz, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.32 (d,
J = 8.0 Hz, 2H), 5.42 (dd, J = 8.4, 2.0 Hz, 1H), 3.67–3.74 (m, 2H), 3.55 (dd, J = 9.0, 3.4 Hz, 1H),
3.32–3.40 (m, 2H), 2.40 (s, 3H), 1.34 (d, J = 6.4 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 194.4, 144.5,
138.4, 137.0, 134.0, 133.4, 131.1, 130.8, 130.0, 128.3, 127.4, 88.8, 72.0, 55.0, 46.3, 21.6, 21.1; HRMS
(ESI+) calcd for [C19H19Cl2NO4S]+: m/z 428.0485, found 428.0476.
1-(3,4-Dimethoxyphenyl)-2-[(2S,4S)-4-methyl-3-tosyloxazolidin-2-yl]ethanone (4h). 90% yield; yellow
1
oil; IR (CH2Cl2) νmax 3064.1, 2974.2, 1672.7, 1595.4, 1346.4, 1163.4 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.64 (d, J = 8.0 Hz, 2H), 7.53 (dd, J = 8.4, 2.0 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.22 (d,
J = 8.0 Hz, 2H), 6.81 (d, J = 8.4 Hz, 1H), 5.40 (dd, J = 8.8, 2.0 Hz, 1H), 3.78–3.81 (m, 7H), 3.62 (ddd,
J = 12.5, 6.1, 3.3 Hz, 1H), 3.56 (d, J = 2.0 Hz, 1H), 3.47 (dd, J = 8.8, 3.6 Hz, 1H), 3.26–3.32 (m, 2H),
13
2.29 (s, 3H), 1.25 (d, J = 6.4 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 195.0, 153.6, 149.0, 144.3,
133.4, 130.0, 127.8, 110.2, 89.3, 71.8, 56.0, 55.0, 45.8, 21.4, 20.9; HRMS (ESI+) calcd for
[C21H25NO6S]+: m/z 420.1475, found 420.1464.
1-(4-Fluorophenyl)-2-[(2S,4S)-4-Methyl-3-tosyloxazolidin-2-yl]ethanone (4i). 51% yield; white solid;
1
IR (CH2Cl2) νmax 3069.4, 2981.0, 1686.4, 1597.3, 1349.2, 1164.7 cm–1; H-NMR (400 MHz, CDCl3)
δ 8.00 (q, J = 1.1 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 7.12 (t, J = 8.8 Hz, 2H),
5.46 (dd, J = 8.8, 2.0 Hz, 1H), 3.67–3.74 (m, 2H), 3.55 (dd, J = 8.8, 3.6 Hz, 1H), 3.35–3.41 (m, 2H),
13
2.39 (s, 3H), 1.34 (d, J = 6.4 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 195.0, 167.2, 164.7, 144.4,
133.4, 133.1, 131.0, 130.1, 127.9, 115.9, 89.0, 71.9, 55.0, 46.2, 21.5, 21.1; HRMS (ESI+) calcd for
[C19H20FNO4S]+: m/z 378.1170, found 378.1170.
2-[(2S,4S)-4-Methyl-3-tosyloxazolidin-2-yl]-1-(naphth-1-yl)ethanone (4j). 84% yield; brown oil; IR
1
(CH2Cl2) νmax 3051.4, 2980.3, 1678.6, 1596.0, 1348.9, 1164.0 cm–1; H-NMR (400 MHz, CDCl3)
δ 8.73 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 7.6 Hz, 2H), 7.84 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H),
7.47–7.59 (m, 3H), 7.28 (d, J = 8.0 Hz, 2H), 5.59 (dd, J = 8.6, 2.2 Hz, 1H), 3.89 (dd, J = 16.4, 2.4 Hz,
1H), 3.75 (ddd, J = 8.1, 4.5, 1.9 Hz, 1H), 3.56 (dd, J = 9.0, 3.4 Hz, 1H), 3.50 (dd, J = 16.8, 8.8 Hz,
13
1H), 3.39 (dd, J = 9.0, 6.2 Hz, 1H), 2.35 (s, 3H), 1.36 (d, J = 6.8 Hz, 3H); C-NMR (100 MHz,

Molecules 2011, 16
3814
CDCl3) δ 200.2, 144.4, 134.9, 134.0, 133.5, 133.3, 130.2, 130.0, 128.6, 128.1, 126.6, 126.0, 124.5,
89.4, 71.9, 55.1, 49.4, 21.5, 21.1; HRMS (ESI+) calcd for [C23H23NO4S]+: m/z 410.1421, found
410.1421.
2-[(2S,4S)-4-Methyl-3-tosyloxazolidin-2-yl]-1-(thien-2-yl)ethanone (4k). 49% yield; brown solid; IR
1
(CH2Cl2) νmax 3102.9, 2980.4, 1658.8, 1597.7, 1348.9, 1164.0 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.78 (dd, J = 3.8, 1.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.65 (dd, J = 5.0, 1.0 Hz, 1H), 7.32 (d,
J = 8.0 Hz, 2H), 7.13 (dd, J = 4.8, 4.0 Hz, 1H), 5.45 (dd, J = 7.6, 3.2 Hz, 1H), 3.72 (ddd, J = 8.0, 4.4,
1.8 Hz, 1H), 3.63 (dd, J = 16.0, 2.0 Hz, 1H), 3.56 (dd, J = 8.8, 3.6 Hz, 1H), 3.32–3.41 (m, 2H), 2.40
13
(s, 3H), 1.34 (d, J = 6.4 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 189.1, 144.4, 144.0, 134.4, 133.4,
132.9, 130.0, 128.4, 127.9, 89.0, 71.9, 55.0, 46.9, 21.6, 21.0; HRMS (ESI+) calcd for [C17H19NO4S2]+:
m/z 366.0828, found 366.0822.
Methyl 2-[(2S,4R)-4-benzyl-3-tosyloxazolidin-2-yl]acetate (5a). 66% yield; white solid; IR (CH2Cl2)
1
νmax 3028.3, 2952.2, 1740.7, 1597.9, 1351.7, 1163.9 cm–1; H-NMR (400 MHz, CDCl3) δ 7.77 (d,
J = 8.4 Hz, 2H), 7.18–7.34 (m, 7H), 5.33 (dd, J = 8.8, 2.8 Hz, 1H), 3.83 (ddd, J = 12.8, 6.4, 3.2 Hz,
1H), 3.72 (dd, J = 9.2, 3.6 Hz, 1H), 3.69 (s, 3H), 3.22 (dd, J = 9.2, 6.4 Hz, 1H), 3.13 (dd, J = 13.6,
3.6 Hz, 1H), 3.06 (dd, J = 15.8, 3.0 Hz, 1H), 2.84 (dd, J = 13.2, 10.0 Hz, 1H), 2.60 (dd, J = 15.8,
13
8.6 Hz, 1H), 2.40 (s, 3H); C-NMR (100 MHz, CDCl3) δ 169.9, 144.5, 137.0, 133.6, 130.1, 129.6,
128.7, 127.9, 126.9, 89.0, 69.1, 60.5, 51.9, 41.8, 40.9, 21.6; HRMS (ESI+) calcd for [C20H23NO5S]+:
m/z 390.1370, found 390.1364.
Ethyl 2-[(2R,4S)-4-benzyl-3-tosyloxazolidin-2-yl]acetate (5b). 81% yield; white solid; IR (CH2Cl2)
1
νmax 3028.3, 2983.2, 1736.0, 1597.9, 1352.0, 1164.1 cm–1; H-NMR (400 MHz, CDCl3) δ 7.75 (dd,
J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 7.6 Hz, 2H), 7.18 (d, J = 8.0 Hz, 3H), 5.33 (dd,
J = 8.8, 2.8 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.82 (ddd, J = 13.0, 6.6, 3.2 Hz, 1H), 3.70 (dd, J = 9.2,
3.2 Hz, 1H), 3.20 (dd, J = 9.2, 6.0 Hz, 1H), 3.13 (dd, J = 13.4, 3.8 Hz, 1H), 3.05 (dd, J = 15.8, 3.0 Hz,
13
1H), 2.83 (dd, J = 13.4, 9.8 Hz, 1H), 2.37 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H); C-NMR (100 MHz,
CDCl3) δ 169.5, 144.5, 137.1, 133.6, 130.1, 129.6, 128.7, 127.9, 126.9, 89.1, 69.1, 60.7, 60.4, 42.0,
41.0, 21.5, 14.2; HRMS (ESI+) calcd for [C21H25NO5S]+: m/z 404.1526, found 404.1528.
Benzyl 2-[(2S,4R)-4-benzyl-3-tosyloxazolidin-2-yl]acetate (5c). 76% yield; yellow oil; IR (CH2Cl2)
νmax 3063.3, 3030.3, 2948.4, 1737.7, 1597.8, 1352.0, 1164.0 cm–1; 1H-NMR (400 MHz, CDCl3) δ 7.81
(d, J = 8.0 Hz, 2H), 7.23–7.42 (m, 12H), 5.44 (dd, J = 8.4, 3.2 Hz, 1H), 5.20 (s, 2H), 3.89 (ddd,
J = 12.9, 6.5, 3.1 Hz, 1H), 3.78 (dd, J = 8.4, 5.2 Hz, 1H), 3.27 (dd, J = 9.2, 6.4 Hz, 1H), 3.16–3.21
13
(m, 2H), 2.88 (dd, J = 13.6, 10.0 Hz, 1H), 2.73 (dd, J = 16.0, 8.4 Hz, 1H), 2.43 (s, 3H); C-NMR
(100 MHz, CDCl3) δ 169.4, 144.6, 137.1, 135.8, 133.7, 130.2, 130.1, 129.6, 128.8, 128.7, 128.5, 128.3,
128.0, 127.0, 89.2, 69.2, 66.7, 60.6, 42.1, 41.0, 21.6; HRMS (ESI+) calcd for [C26H27NO5S]+: m/z
466.1683, found 466.1687.
Phenyl 2-[(2S,4R)-4-benzyl-3-tosyloxazolidin-2-yl]acetate (5d). 5% yield; yellow oil; IR (CH2Cl2) νmax
1
3028.5, 2924.3, 1712.3, 1589.8, 1325.3, 1362.2 cm–1; H-NMR (400 MHz, CDCl3) δ 7.80 (d,

Molecules 2011, 16
3815
J = 8.4 Hz, 2H), 7.05–7.42 (m, 12H), 5.42 (dd, J = 8.0, 3.2 Hz, 1H), 3.86 (ddd, J = 13.1, 6.3, 3.3 Hz,
1H), 3.79 (dd, J = 9.2, 3.2 Hz, 1H), 3.33 (dd, J = 16.0, 3.2 Hz, 1H), 3.27 (dd, J = 9.0, 6.2 Hz, 1H), 3.20
13
(dd, J = 13.6, 3.6 Hz, 1H), 2.82–2.92 (m, 3H), 2.43 (s, 3H); C-NMR (100 MHz, CDCl3) δ 167.0,
159.8, 155.7, 143.4, 137.5, 136.3, 129.7, 127.0, 128.0, 101.1, 64.5, 54.1, 38.8, 21.5; HRMS (ESI+)
calcd for [C25H25NO5S]+: m/z 452.1526, found 452.1515.
1-[(2S,4S)-4-Benzyl-3-tosyloxazolidin-2-yl]propan-2-one (5e). 45% yield; yellow oil; IR (CH2Cl2) νmax
1
3062.3, 2924.8, 1716.7, 1598.0, 1349.8, 1163.6 cm–1; H-NMR (400 MHz, CDCl3) δ 7.74 (d,
J = 8.4 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 7.6 Hz, 2H), 7.19–7.22 (m, 3H), 5.27 (dd,
J = 8.4, 2.4 Hz, 1H), 3.80 (ddd, J = 9.4, 6.2, 3.2 Hz, 1H), 3.69 (dd, J = 9.2, 2.8 Hz, 1H), 3.10–3.17 (m,
3H), 2.83 (dd, J = 13.6, 10.0 Hz, 1H), 2.72 (dd, J = 16.8, 8.4 Hz, 1H), 2.40 (s, 3H), 2.13 (s, 3H);
13C- NMR (100 MHz, CDCl3) δ 205.1, 144.5, 137.1, 133.5, 13071, 129.7, 128.7, 127.9, 126.9, 88.6, 69.0,
60.3, 50.2, 41.0, 30.8, 21.6; HRMS (ESI+) calcd for [C20H23NO4S]+: m/z 374.1421, found 374.1413.
2-[(2S,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-phenylethanone (5f). 71% yield; white solid; IR
1
(CH2Cl2) νmax 3060.0, 3027.9, 2924.2, 1687.4, 1597.2, 1349.6, 1163.3 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.92 (d, J = 7.2 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.24–7.58 (m, 9H), 5.55 (dd, J = 8.8,
2.0 Hz, 1H), 3.89 (ddd, J = 9.4, 6.2, 3.4 Hz, 1H), 3.75 (dd, J = 9.6, 3.2 Hz, 1H), 3.63 (dd, J = 16.8,
13
2.0 Hz, 1H), 3.13–3.28 (m, 3H), 2.97 (dd, J = 13.4, 9.4 Hz, 1H), 2.40 (s, 3H); C-NMR (100 MHz,
CDCl3) δ 196.6, 144.5, 137.1 ,136.6, 133.5, 130.1, 130.0, 129.1, 128.7, 128.3, 128.0, 127.0, 89.2, 69.0,
60.2, 45.6, 40.8, 21.6; HRMS (ESI+) calcd for [C25H25NO4S]+: m/z 436.1577, found 436.1576.
2-[(2R,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-(3,4-dichlorophenyl)ethanone (5g). 30% yield; white
1
solid; IR (CH2Cl2) νmax 3063.5, 3028.4, 2924.0, 1691.4, 1597.7, 1350.47, 1164.0 cm–1; H-NMR
(400 MHz, CDCl3) δ 7.94 (d, J = 2.0 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.72 (dd, J = 8.4, 2.0 Hz, 1H),
7.54 (d, J = 8.4 Hz, 2H), 7.25–7.37 (m, 8H), 5.46 (dd, J = 8.6, 2.2 Hz, 1H), 3.87 (ddd, J = 9.1, 6.1,
3.1 Hz, 1H), 3.76 (dd, J = 9.2, 3.2 Hz, 1H), 3.51 (dd, J = 16.8, 2.0 Hz, 1H), 3.28 (dd, J = 9.2, 6.4 Hz,
13
1H), 2.96–3.12 (m, 3H), 2.43 (s, 3H); C-NMR (100 MHz, CDCl3) δ 194.4, 144.6, 138.0, 136.9,
136.0, 133.4, 133.3, 130.8, 130.3, 130.1, 128.7, 127.9, 127.3, 127.0, 88.9, 69.0, 60.0, 45.5, 40.6, 21.6;
HRMS (ESI+) calcd for [C25H23Cl2NO4S]+: m/z 504.0798, found 504.0802.
2-[(2R,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-(3,4-dimethoxyphenyl)ethanone (5h). 98% yield; yellow
1
oil; IR (CH2Cl2) νmax 3062.0, 3027.3, 2936.2, 1672.8, 1595.7, 1347.3, 1163.2 cm–1; H-NMR
(400 MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 2H), 7.45–7.54 (m, 2H), 7.24 (t, J = 7.2 Hz, 2H), 7.17 (d,
J = 14.0 Hz, 2H), 6.90–6.93 (m, 1H), 6.84 (d, J = 8.4 Hz, 1H), 5.47 (dd, J = 8.8, 2.0 Hz, 1H), 3.85 (s,
3H), 3.83 (s, 3H), 3.68 (dd, J = 9.0, 3.4 Hz, 1H), 3.52 (dd, J = 16.4, 1.6 Hz, 1H), 3.19 (dd, J = 9.2,
13
6.4 Hz, 1H), 3.04–3.13 (m, 1H), 2.88 (dd, J = 13.4, 9.4 Hz, 1H), 2.31 (s, 3H); C-NMR (100 MHz,
CDCl3) δ 195.1, 153.6, 149.0, 144.4, 143.0, 137.5, 137.3, 137.0, 133.4, 130.1, 130.0, 129.9, 129.8,
126.8, 110.1, 89.4, 68.9, 56.8, 56.1, 55.9, 45.1, 40.6, 21.5, 21.0; HRMS (ESI+) calcd for
[C27H29NO6S]+: m/z 496.1788, found 496.1779.

Molecules 2011, 16
3816
2-[(2R,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-(4-fluorophenyl)ethanone (5i). 51% yield; yellow solid;
1
IR (CH2Cl2) νmax 3063.5, 3028.6, 2924.9, 1686.4, 1597.2, 1350.0, 1163.9 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.93 (dd, J = 8.8, 5.6 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.10–7.34 (m, 9H), 5.50 (dd, J = 8.8,
2.0 Hz, 1H), 3.87 (ddd, J = 9.3, 6.3, 3.1 Hz, 1H), 3.75 (dd, J = 9.2, 3.2 Hz, 1H), 3.52 (dd, J = 16.8,
2.0 Hz, 1H), 3.25 (dd, J = 9.2, 6.0 Hz, 1H), 2.98–3.18 (m, 2H), 2.95 (dd, J = 13.6, 9.6 Hz, 1H), 2.40
13
(s, 3H); C-NMR (100 MHz, CDCl3) δ 195.0, 167.2, 164.7, 144.5, 137.0, 133.5, 133.1, 131.1, 131.0,
130.2, 130.0, 128.7, 128.0, 127.0, 115.8, 89.2, 69.0, 60.2, 45.5, 40.8, 21.6; HRMS (ESI+) calcd for
[C25H24FNO4S]+: m/z 454.1483, found 454.1489.
2-[(2R,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-(naphth-1-yl)ethanone (5j). 96% yield; yellow oil; IR
1
(CH2Cl2) νmax 3060.6, 3028.6, 2924.4, 1678.7, 1596.3, 1349.6, 1163.4 cm–1; H-NMR (400 MHz,
CDCl3) δ 8.82 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.84–7.90 (m, 4H), 7.50–7.62 (m, 3H),
7.22–7.35 (m, 7H), 5.66 (dd, J = 8.6, 2.2 Hz, 1H), 3.94 (ddd, J = 9.3, 6.3, 3.1 Hz, 1H), 3.78–3.85
(m, 2H), 3.34 (dd, J = 16.8, 8.8 Hz, 1H), 3.28 (dd, J = 9.2, 6.0 Hz, 1H), 3.18 (dd, J = 13.4, 3.4 Hz, 1H),
13
2.98 (dd, J = 13.6, 9.2 Hz, 1H), 2.36 (s, 3H); C-NMR (100 MHz, CDCl3) δ 200.1, 144.5, 137.1,
134.9, 134.0, 133.6, 133.4, 130.3, 130.2, 130.0, 128.9, 128.7, 128.6, 128.2, 128.0, 127.0, 126.6, 126.0,
127.5, 89.7, 69.1, 60.4, 48.8, 40.9, 21.6; HRMS (ESI+) calcd for [C29H27NO4S]+: m/z 486.1734, found
486.1729.
2-[(2R,4R)-4-Benzyl-3-tosyloxazolidin-2-yl]-1-(thien-2-yl)ethanone (5k). 41% yield; brown solid; IR
1
(CH2Cl2) νmax 3105.0, 3028.7, 2918.5, 1660.9, 1597.4, 1350.3, 1163.1 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.79 (d, J = 8.0 Hz, 2H), 7.69 (dd, J = 3.8, 1.0 Hz, 1H), 7.66 (dd, J = 5.0, 1.0 Hz, 1H), 7.33
(t, J = 7.2 Hz, 4H), 7.25 (d, J = 6.8 Hz, 3H), 7.14 (t, J = 2.6 Hz, 1H), 5.47 (dd, J = 8.6, 2.2 Hz, 1H),
3.86 (ddd, J = 9.4, 6.2, 3.2 Hz, 1H), 3.76 (dd, J = 9.2, 3.2 Hz, 1H), 3.54 (dd, J = 16.2, 2.2 Hz, 1H),
3.25 (dd, J = 9.2, 6.4 Hz, 1H), 3.09–3.15 (m, 2H), 2.94 (dd, J = 13.6, 9.6 Hz, 1H), 2.42 (s, 3H);
13C- NMR (100 MHz, CDCl3) δ 189.2, 144.6, 144.1, 137.1, 134.5, 134.4 ,133.5, 132.9, 130.2, 130.0,
128.7, 128.3, 128.0, 127.0, 89.2, 69.0, 60.2, 46.2, 40.7, 21.6; HRMS (ESI+) calcd for [C23H23NO4S2]+:
m/z 442.1141, found 442.1119.
Methyl 2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]acetate (6a). 38% yield; yellow oil; IR
1
(CH2Cl2) νmax 3532.4, 2953.5, 1738.3. 1597.5. 1349.3. 1164.0 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.73 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 5.31 (dd, J = 8.2, 3.4 Hz, 1H), 3.87 (dd, J = 9.0,
3.4 Hz, 1H), 3.63–3.69 (m, 6H), 3.44 (dd, J = 9.0, 6.2 Hz, 1H), 3.03 (dd, J = 15.6, 3.6 Hz, 1H), 2.75
13
(dd, J = 16.0, 8.0 Hz, 1H), 2.41 (s, 3H); C-NMR (100 MHz, CDCl3) δ 170.0, 144.8, 133.0, 130.2,
128.0, 127.0, 89.1, 67.6, 63.1, 60.2, 52.0, 41.3, 21.6; HRMS (ESI+) calcd for [C14H19NO6S]+: m/z
330.1006, found 330.0995.
Ethyl 2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]acetate (6b). 50% yield; brown oil; IR
1
(CH2Cl2) νmax 3531.9, 2982.6, 1732.1, 1597.6, 1350.5, 1164.6 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.73 (d, J = 8.4 Hz, 2H), 7.33 (dd, J = 8.0 Hz, 2H), 5.31 (dd, J = 8.2, 3.4 Hz, 1H), 4.14 (q, J = 7.2
Hz, 2H), 3.87 (dd, J = 9.4, 3.4 Hz, 1H), 3.63–3.70 (m, 3H), 3.44 (dd, J = 9.0, 6.2 Hz, 1H), 3.01 (dd,
J = 15.8, 3.4 Hz, 2H), 2.73 (dd, J = 15.8, 8.2 Hz, 1H), 2.37–2.41 (m, 4H), 1.24 (t, J = 7.2 Hz, 3H); 13C-

Molecules 2011, 16
3817
NMR (100 MHz, CDCl3) δ 169.6, 144.8, 133.1, 130.1, 128.0, 89.1, 67.6, 63.2, 61.0, 60.2, 41.5, 21.6,
14.1; HRMS (ESI+) calcd for [C15H21NO6S]+: m/z 344.1162, found 344.1186.
Benzyl 2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]acetate (6c). 37% yield; brown oil; IR
1
(CH2Cl2) νmax 3532.5, 3064.1, 2949.6, 1736.5, 1597.4, 1350.1, 1164.3 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.33–7.37 (m, 7H), 5.38 (dd, J = 8.0, 3.6 Hz, 1H), 5.16 (s, 2H), 3.89
(dd, J = 9.2, 3.6 Hz, 1H), 3.64–3.73 (m, 3H), 3.46 (dd, J = 9.2, 6.4 Hz, 1H), 3.10 (dd, J = 15.6, 3.6 Hz,
1H), 2.83 (dd, J = 15.6, 8.0 Hz, 1H), 2.42 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 169.5, 144.8, 141.0,
135.5, 133.1, 130.2, 128.6, 128.3, 128.0, 127.0, 89.1, 67.6, 66.8, 65.1, 63.2, 60.2, 41.5, 21.6; HRMS
(ESI+) calcd for [C20H23NO6S]+: m/z 406.1319, found 406.1327.
Phenyl 2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]acetate (6d). 8% yield; yellow oil; IR
1
(CH2Cl2) νmax 3515.0, 3064.8, 2526.4, 1755.0, 1594.6, 1324.6, 1163.1 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.77 (d, J = 3.2 Hz, 2H), 7.74 (d, J = 4.4 Hz, 2H), 7.05–7.15 (m, 5H), 5.48 (dd, J = 7.6,
4.0 Hz, 1H), 3.95 (dd, J = 9.0, 3.8 Hz, 1H), 3.72–3.76 (m, 2H), 3.46–3.57 (m, 3H), 3.31 (dd, J = 15.4,
13
3.8 Hz, 1H), 3.03 (dd, J = 15.6, 7.6 Hz, 1H), 2.45 (s, 3H); C-NMR (100 MHz, CDCl3) δ 168.1,
150.4, 144.9, 143.7, 133.0, 130.2, 130.1, 129.8, 129.4, 128.0, 127.1, 121.6, 118.0, 100.8, 89.1, 67.7,
63.3, 62.4, 54.1, 41.6, 21.6; HRMS (ESI+) calcd for [C19H21NO6S]+: m/z 392.1162, found 392.1187.
1-[(2S,4R)-4-(Hydroxymethyl)-3-tosyloxazolidin-2-yl]propan-2-one (6e). 29% yield; yellow oil; IR
1
(CH2Cl2) νmax 3516.2, 3060.0, 2953.8, 1715.3, 1597.3, 1348.3, 1163.9 cm–1; H NMR (400 MHz,
CDCl3) δ 7.72 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 5.28 (dd, J = 8.0, 2.8 Hz, 1H), 3.84 (dd,
J = 10.4, 2.8 Hz, 1H), 3.67 (s, 3H), 3.35–3.39 (m, 1H), 3.15 (dd, J = 16.8, 2.8 Hz, 1H), 2.92 (dd,
J = 16.8, 8.0 Hz, 2H), 2.42 (s, 3H), 2.19 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.3, 144.8, 132.9,
130.2, 128.0, 88.7, 67.7, 63.5, 60.0, 49.8, 30.9, 21.6; HRMS (ESI+) calcd for [C14H19NO5S]+: m/z
314.1057, found 314.1050.
2-[(2S,4R)-4-(Hydroxymethyl)-3-tosyloxazolidin-2-yl]-1-phenylethanone (6f). 23% yield; brown solid;
1
IR (CH2Cl2) νmax 3515.4, 3061.5, 2933.4, 1687.2, 1597.1, 1347.7, 1163.3 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.96 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.54–7.58 (m, 1H), 7.45 (t, J = 7.6 Hz,
2H), 7.34 (d, J = 8.0 Hz, 2H), 5.53 (dd, J = 8.4, 2.4 Hz, 1H), 3.88 (dd, J = 8.6, 2.2 Hz, 1H), 3.68–3.72
(m, 4H), 3.47 (dd, J = 16.8, 8.4 Hz, 1H), 3.39–3.42 (m, 1H), 2.41 (s, 3H); 13C-NMR (100 MHz,
CDCl3) δ 196.7, 144.8, 136.5, 133.6, 133.0, 130.2, 130.0, 128.7, 128.3, 128.0, 89.3, 67.8, 63.5, 60.1,
45.5, 21.6; HRMS (ESI+) calcd for [C19H21NO5S]+: m/z 376.1213, found 376.1187.
1-(3,4-Dichlorophenyl)-2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]ethanone (6g). 12%
yield; brown oil; IR (CH2Cl2) νmax 3513.6, 3064.1, 2925.2, 1691.4, 1584.1, 1333.8, 1162.5 cm–1;
1H- NMR (400 MHz, CDCl3) δ 8.05 (d, J = 2.0 Hz, 1H), 7.80 (d, J = 7.6 Hz, 2H), 7.37 (d, J = 8.0 Hz,
2H), 7.28 (d, J = 7.6 Hz, 2H), 5.48 (dd, J = 8.2, 2.6 Hz, 1H), 3.88 (dd, J = 8.6, 2.2 Hz, 1H), 3.66–3.77
13
(m, 7H), 3.39–3.45 (m, 2H), 2.45 (s, 3H), 2.40–2.42 (m, 4H); C-NMR (100 MHz, CDCl3) δ 194.4,
145.0, 144.2, 138.2, 136.1, 133.5, 132.8, 131.0, 130.9, 128.0, 127.3, 127.2, 126.9, 126.4, 89.1, 60.1,
53.4, 21.6; HRMS (ESI+) calcd for [C19H19Cl2NO5S]+: m/z 444.0434, found 444.0388.

Molecules 2011, 16
3818
1-(3,4-Dimethoxyphenyl)-2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]ethanone (6h). 38% yield;
1
yellow oil; IR (CH2Cl2) νmax 3268.9, 3060.0, 2966.1, 1673.8, 1595.8, 1334.0, 1149.5 cm–1; H- NMR
(400 MHz, CDCl3) δ 7.73 (d, J = 8.4 Hz, 2H), 7.49 (dd, J = 8.4, 2.0 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H),
7.22 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 8.4 Hz, 1H), 6.07 (d, J = 9.6 Hz, 1H), 5.13 (t, J = 5.0 Hz, 1H),
3.88 (s, 3H), 3.73–3.84 (m, 6H), 3.27 (d, J = 9.6 Hz, 1H), 3.22 (d, J = 4.8 Hz, 2H), 2.34 (s, 3H);
13C-NMR (100 MHz, CDCl3) δ 194.6, 194.5, 153.6, 149.0, 148.9, 143.7, 143.5, 138.1, 137.7, 130.0,
129.8, 127.0, 126.8, 123.4, 110.1, 100.0, 70.5, 56.0, 47.8, 45.3, 43.1, 42.8, 21.5; HRMS (ESI+) calcd
for [C21H25NO7S]+: m/z 436.1425, found 436.1418.
1-(4-Fluorophenyl)-2-[(2S,4R)-4-(hydroxymethyl)-3-tosyloxazolidin-2-yl]ethanone (6i). 23% yield;
1
brown oil; IR (CH2Cl2) νmax 3515.7, 3064.1, 2925.2, 1687.0, 1597.5, 1346.7, 1163.5 cm–1; H-NMR
(400 MHz, CDCl3) δ 8.00 (dd, J = 8.8, 5.6 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H),
7.12 (t, J = 8.6 Hz, 2H), 5.51 (dd, J = 8.4, 2.4 Hz, 1H), 3.88 (dd, J = 8.4, 2.0 Hz, 1H), 3.65–3.74
13
(m, 5H), 3.39–3.48 (m, 2H), 2.43 (s, 3H), 2.38–2.41 (m, 1H); C-NMR (100 MHz, CDCl3) δ 195.1,
144.9, 132.9, 132.4, 132.3, 131.1, 131.0, 130.2, 129.1, 128.0, 89.3, 67.8, 63.4, 60.1, 45.4, 22.6, 21.6;
HRMS (ESI+) calcd for [C19H20FNO5S]+: m/z 394.1119, found 394.1100.
2-[(2S,4R)-4-(Hydroxymethyl)-3-tosyloxazolidin-2-yl]-1-(naphth-1-yl)ethanone (6j). 24% yield; brown
1
oil; IR (CH2Cl2) νmax 3515.8, 3052.0, 2957.9, 1678.1, 1509.0, 1346.9, 1163.1 cm–1; H-NMR
(400 MHz, CDCl3) δ 8.70 (d, J = 8.0 Hz, 1H), 7.98 (dd, J = 9.0, 4.6 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H),
7.48–7.60 (m, 4H), 7.33 (d, J = 8.0 Hz, 2H), 5.58 (dd, J = 8.4, 2.8 Hz, 1H), 3.86–3.91 (m, 2H),
3.65–3.78 (m, 4H), 3.52 (dd, J = 16.4, 8.4 Hz, 1H), 3.42 (dd, J = 9.0, 6.2 Hz, 1H), 2.41 (s, 3H);
13C-NMR (100 MHz, CDCl3) δ 200.2, 144.8, 134.9, 134.0, 133.8, 133.4, 133.0, 130.2, 128.7, 128.6,
128.5, 125.9, 89.8, 76.8, 60.4, 48.7, 21.5, 21.1; HRMS (ESI+) calcd for [C23H23NO5S]+: m/z 426.1370,
found 426.1365.
2-[(2R,4R)-4-(Hydroxymethyl)-3-tosyloxazolidin-2-yl]-1-(thien-2-yl)ethanone (6k). 58% yield; brown
1
oil; IR (CH2Cl2) νmax 3270.0, 3096.8, 2974.2, 1658.6, 1597.8, 1332.4, 1162.3 cm–1; H-NMR
(400 MHz, CDCl3) δ 7.75 (dd, J = 8.2, 2.2 Hz, 2H), 7.67 (dd, J = 3.6, 1.2 Hz, 1H), 7.61 (d, J = 4.8 Hz,
1H), 7.25 (d, J = 9.6 Hz, 2H), 7.05–7.07 (m, 1H), 6.08 (d, J = 8.0 Hz, 1H), 5.11 (t, J = 4.4 Hz, 1H),
3.78 (q, J = 13.9 Hz, 3H), 3.20 (d, J = 5.2 Hz, 2H), 2.36 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 188.7,
144.2, 143.8, 143.6, 137.6, 134.6, 133.2, 133.1, 129.9, 128.4, 127.0, 99.4, 70.5, 69.9, 47.7, 44.3, 21.5;
HRMS (ESI+) calcd for [C17H19NO5S2]+: m/z 382.0777, found 382.0781.
Methyl 2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}acetate (7a). 15% yield; white oil; IR
1
(CH2Cl2) νmax 2916.8, 2848.7, 1715.4, 1631.7, 1349.0, 1160.9 cm–1; H-NMR (400 MHz, CDCl3)
δ 8.38 (d, J = 8.0 Hz, 2H), 8.13 (d, J = 8.0 Hz, 2H), 5.26 (dd, J = 8.0, 4.0 Hz, 1H), 3.68 (s, 3H),
3.42–3.48 (m, 1H), 3.15 (ddd, J = 13.0, 9.0, 3.0 Hz, 1H), 2.74 (dd, J = 16.0, 4.0 Hz, 1H), 2.46 (s, 3H),
2.29–2.34 (m, 1H), 1.96–1.98 (m, 1H), 1.77–1.81 (m, 2H), 1.40–1.43 (m, 1H), 1.30–1.35 (m, 4H);
13C-NMR (100 MHz, CDCl3) δ 171.4, 152.2, 147.5, 143.2, 136.5, 127.2, 121.1, 118.0, 110.0, 88.1,
60.2, 50.9, 39.3, 37.4, 29.7, 21.4; GCMS (EI+) calcd for [C17H23NO5S]: m/z 354.4, found 355.0.

Molecules 2011, 16
3819
Ethyl 2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}acetate (7b). 37% yield; white oil; IR
1
(CH2Cl2) νmax 2942.9, 1736.4, 1598.4, 1352.7, 1162.7 cm–1; H-NMR (400 MHz, CDCl3) δ 7.68 (d,
J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 5.32 (dd, J = 9.6, 2.4 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H);
13C- NMR (100 MHz, CDCl3) δ 169.8, 144.4, 131.7, 130.0, 129.8, 128.2, 127.4, 88.3, 80.2, 64.5, 63.3,
60.7, 41.8, 29.6, 29.0, 24.4, 23.8, 23.3, 23.1, 21.6, 14.2; HRMS (ESI+) calcd for [C18H25NO5S]+: m/z
368.1526, found 368.1529.
Benzyl 2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}acetate (7c). 19% yield; yellow oil; IR
1
(CH2Cl2) νmax 3032.7, 2940.8, 2862.9, 1710.7, 1620.9, 1320.5, 1121.0 cm–1; H-NMR (400 MHz,
CDCl3) δ 7.74 (d, J = 8.0 Hz, 2H), 7.36–7.38 (m, 5H), 7.23 (d, J = 8.0 Hz, 2H), 5.10 (s, 1H), 5.07
(s, 1H), 4.88 (s, 1H), 3.67 (ddd, J = 10.0, 6.0, 2.0 Hz, 1H), 3.42 (t, J = 8.0 Hz, 1H), 3.06–3.11 (m, 1H),
2.78 (t, J = 8.0 Hz, 1H), 2.39 (s, 3H), 2.25–2.27 (m, 1H), 1.98–2.02 (m, 1H), 1.74–1.83 (m, 1H),
13
1.66–1.70 (m, 1H), 1.53–1.61 (m, 1H), 1.24–1.31 (m, 3H); C-NMR (100 MHz, CDCl3) δ 169.9,
167.1, 167.0, 163.4, 160.6, 149.1, 145.1, 144.9, 143.1, 137.1, 136.4, 136.1, 135.5, 135.3, 135.2, 130.0,
129.9, 129.5, 128.4, 127.3, 102.9, 102.8, 98.0, 79.6, 77.3, 67.3, 67.1, 66.2, 65.6, 55.8, 51.5, 32.2, 31.2,
29.6, 28.8, 28.0, 25.0, 23.2, 21.7, 21.5; GCMS (EI+) calcd for [C23H27NO5S]: m/z 429.5, found 430.0.
Phenyl 2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}acetate (7d). 13% yield; white solid; IR
1
(CH2Cl2) νmax 3056.0, 2943.7, 1758.4, 1597.1, 1352.8, 1163.5 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.73 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 4H), 7.21–7.25 (m, 1H), 7.12 (dd, J = 5.0, 3.8 Hz, 2H),
5.44 (dd, J = 9.4, 2.6 Hz, 1H), 3.58–3.61 (m, 1H), 3.38 (dd, J = 16.2, 2.6 Hz, 1H), 3.05 (dd, J = 16.2,
9.0 Hz, 1H), 2.45–2.50 (m, 4H), 2.37 (ddd, J = 12.0, 8.0, 4.0 Hz, 1H), 1.84–2.07 (m, 1H), 1.81–1.84
(m, 2H), 1.51 (dd, J = 12.0, 3.6 Hz, 1H), 1.24–1.32 (m, 4H), 0.86–0.90 (m, 1H); 13C-NMR (100 MHz,
CDCl3) δ 168.3, 150.5, 144.5, 131.6, 130.0, 129.4, 129.1, 128.2, 126.0, 121.6, 88.2, 80.6, 64.6, 42.1,
29.7, 29.1, 23.8, 23.3, 21.6; HRMS (ESI+) calcd for [C22H25NO5S]+: m/z 416.1526, found 416.1525.
1-{(2S,3aS,7aS)-3-Tosyloctahydrobenzo[d]oxazol-2-yl}propan-2-one (7e). 33% yield; yellow solid; IR
1
(CH2Cl2) νmax 3060.9, 2943.0, 1717.2, 1598.3, 1351.3, 1162.1 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.63 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 5.30 (dd, J = 9.2, 2.0 Hz, 1H), 3.42 (ddd, J = 10.9,
9.1, 2.7 Hz, 1H), 3.13 (dd, J = 13.6, 6.0 Hz, 1H), 2.95 (dd, J = 17.2, 9.2 Hz, 1H), 2.36–2.43 (m, 5H),
2.21–2.27 (m, 1H), 2.17 (s, 3H), 1.94–1.96 (m, 1H), 1.71–1.77 (m, 2H), 1.36–1.46 (m, 1H), 1.15–1.23
13
(m, 4H); C-NMR (100 MHz, CDCl3) δ 205.4, 144.4, 131.5, 130.0, 128.1, 127.3, 87.7, 80.3, 64.3,
50.3, 30.7, 29.6, 29.3, 29.0, 23.7, 23.3, 21.6; HRMS (ESI+) calcd for [C17H23NO4S]+: m/z 338.1421,
found 338.1416.
1-Phenyl-2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}ethanone (7f). 32% yield; yellow oil;
1
IR (CH2Cl2) νmax 3056.0, 2942.4, 1687.0, 1597.5, 1350.5, 1162.7 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.99 (dd, J = 8.4, 1.2 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.54–7.58 (m, 1H), 7.47 (dd, J = 8.0, 7.2 Hz,
2H), 7.35 (d, J = 8.0 Hz, 2H), 5.57 (dd, J = 9.2, 2.0 Hz, 1H), 3.71 (dd, J = 17.2, 2.0 Hz, 1H), 3.48–3.54
(m, 2H), 2.49 (dd, J = 12.6, 2.2 Hz, 1H), 2.43 (s, 3H), 2.32 (ddd, J = 11.9, 8.7, 2.9 Hz, 1H), 1.81–2.02
(m, 1H), 1.75–1.81 (m, 2H), 1.50 (dd, J = 12.6, 3.0 Hz, 1H), 1.20–1.27 (m, 3H); 13C-NMR (100 MHz,

Molecules 2011, 16
3820
CDCl3) δ 196.8, 144.5, 136.6, 133.4, 131.5, 130.0, 128.7, 128.3, 127.4, 88.3, 80.4, 64.4, 45.8, 29.6,
29.0, 23.8, 23.3, 21.6; HRMS (ESI+) calcd for [C22H25NO4S]+: m/z 400.1577, found 400.1582.
1-(3,4-Dichlorophenyl)-2-(3-tosyloctahydrobenzo[d]oxazol-2-yl)ethanone (7g). 18% yield; yellow
1
solid; IR (CH2Cl2) νmax 3068.0, 2946.6, 2863.7, 1685.3, 1583.9, 1351.1, 1163.7 cm–1; H-NMR
(400 MHz, CDCl3) δ 8.06 (s, 1H), 7.81 (dd, J = 10.0, 2.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.55 (d,
J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 2H), 5.50 (dd, J = 10.0, 2.0 Hz, 1H), 3.68 (dd, J = 16.0, 4.0 Hz,
1H), 3.51 (td, J = 10.0, 4.0 Hz, 1H), 3.45 (dd, J = 18.0, 10.0 Hz, 1H), 2.48 (dd, J = 14.0, 2.0 Hz, 1H),
2.44 (s, 3H), 2.31 (ddd, J = 12.0, 8.0, 4.0 Hz, 1H), 1.97–1.99 (m, 1H), 1.76–1.82 (m, 2H), 1.45–1.54
(m, 1H), 1.20–1.27 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 194.6, 144.6, 138.0, 136.1, 133.4, 130.9,
130.3, 129.9, 128.3, 128.2, 127.5, 127.4, 127.3, 88.0, 80.5, 77.3, 64.3, 45.9, 29.6, 29.0, 23.8, 23.3,
21.6; GCMS (EI+) calcd for [C22H23Cl2NO4S]: m/z 468.4, found 468.1.
1-(3,4-Dimethoxyphenyl)-2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}ethanone (7h) 93%
1
yield; yellow solid; IR (CH2Cl2) νmax 2938.9, 1672.7, 1596.0, 1348.4, 1161.1 cm–1; H-NMR
(400 MHz, CDCl3) δ 7.61 (d, J = 8.4 Hz, 2H), 7.56 (dd, J = 8.4, 1.6 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H),
7.26 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 5.48 (d, J = 7.6 Hz, 1H),
3.83 (s, 3H), 3.82 (s, 3H), 3.38–3.60 (m, 3H), 3.21 (ddd, J = 11.8, 7.8, 2.2 Hz, 1H), 2.21–2.40 (m, 5H),
13
1.84–1.92 (m, 2H), 1.61–1.70 (m, 3H), 1.37–1.46 (m, 2H), 1.11–1.18 (m, 4H); C-NMR (100 MHz,
CDCl3) δ 195.4, 153.5, 149.0, 144.4, 143.2, 137.7, 131.4, 130.0, 129.7, 128.1, 127.0, 110.2, 88.5, 80.2,
72.9, 64.3, 59.6, 56.0, 54.3, 33.3, 31.5, 29.6, 29.0, 24.6, 23.7, 21.4; HRMS (ESI+) calcd for
[C22H23Cl2NO4S]+: m/z 468.0798, found 468.0830.
1-(4-Fluorophenyl)-2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}ethanone (7i). 27% yield;
1
yellow solid; IR (CH2Cl2) νmax 2942.4, 1687.2, 1597.4, 1350.7, 1162.6 cm–1; H-NMR (400 MHz,
CDCl3) δ 8.01 (t, J = 4.4 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.14 (t,
J = 8.8 Hz, 2H), 5.53 (dd, J = 9.2, 1.6 Hz, 1H), 3.69 (dd, J = 17.0, 1.8 Hz, 1H), 3.44–3.54 (m, 2H),
2.42–2.50 (m, 5H), 2.31 (ddd, J = 11.7, 8.9, 3.1 Hz, 1H), 1.97–2.00 (m, 1H), 1.75–1.81 (m, 2H), 1.50
13
(ddd, J = 18.1, 12.1, 6.1 Hz, 1H), 1.19–1.27 (m, 3H); C-NMR (100 MHz, CDCl3) δ 195.2, 167.1,
164.6, 144.5, 134.3, 133.1, 133.0, 132.0, 131.7, 131.0, 128.2, 115.9, 88.2, 80.4, 64.4, 45.7, 31.5, 29.7,
23.9, 23.3, 21.6; HRMS (ESI+) calcd for [C22H24FNO4S]+: m/z 418.1483, found 418.1496.
1-(Naphth-1-yl)-2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}ethanone (7j). 33% yield;
brown oil; IR (CH2Cl2) νmax 3056.0, 2942.5, 1678.0, 1596.5, 1350.8, 1162.5 cm–1; 1H-NMR (400 MHz,
CDCl3) δ 8.75 (d, J = 8.4, 1H), 7.99 (d, J = 6.8 Hz, 2H), 7.86 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.4 Hz,
2H), 7.51–7.61 (m, 4H), 7.33 (d, J = 8.0 Hz, 2H), 5.63 (dd, J = 9.2, 2.0 Hz, 1H), 3.88 (dd, J = 16.8,
2.0 Hz, 1H), 3.54–3.62 (m, 2H), 2.51 (d, J = 12.0 Hz, 1H), 2.41 (s, 3H), 2.35 (ddd, J = 11.7, 9.1,
3.1 Hz, 1H), 1.99–2.03 (m, 1H), 1.75–1.81 (m, 2H), 1.46–1.52 (m, 1H), 1.20–1.29 (m, 3H); 13C-NMR
(100 MHz, CDCl3) δ 200.5, 144.5, 134.9, 134.0, 133.3, 131.5, 130.3, 130.0, 128.7, 128.5, 127.5, 127.4,
126.6, 124.4, 88.7, 80.4, 64.5, 48.9, 29.7, 29.1, 23.9, 23.8, 21.6; HRMS (ESI+) calcd for
[C26H27NO4S]+: m/z 450.1734, found 450.1732.

Molecules 2011, 16
3821
1-(Thien-2-yl)-2-{(2S,3aS,7aS)-3-tosyloctahydrobenzo[d]oxazol-2-yl}ethanone (7k). 25% yield; brown
1
solid; IR (CH2Cl2) νmax 2943.0, 1659.0, 1598.0, 1350.8, 1162.2 cm–1; H-NMR (400 MHz, CDCl3)
δ 7.80 (dd, J = 3.8, 1.0 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.65 (dd, J = 5.0, 1.0 Hz, 1H), 7.35 (d,
J = 8.0 Hz, 2H), 7.14 (dd, J = 5.0, 3.8 Hz, 1H), 5.51 (dd, J = 9.2, 2.0 Hz, 1H), 3.63 (dd, J = 16.4,
2.0 Hz, 1H), 3.54 (ddd, J = 10.9, 8.9, 2.9 Hz, 1H), 3.44 (dd, J = 16.2, 8.6 Hz, 1H), 2.41–2.49 (m, 4H),
2.31 (ddd, J = 12.2, 8.6, 3.0 Hz, 1H), 1.97–1.99 (m, 1H), 1.75–1.81 (m, 2H), 1.44–1.50 (m, 1H),
13
1.16–1.27 (m, 3H); C-NMR (100 MHz, CDCl3) δ 189.4, 144.5, 144.0, 134.2, 132.6, 131.5, 130.0,
128.3, 88.3, 80.4, 64.4, 46.4, 29.6, 29.0, 23.8, 23.3, 21.6; HRMS (ESI+) calcd for [C20H23NO4S2]+: m/z
406.1141, found 406.1136.
(2S,4S)-4-Isopropyl-3-tosyl-2-(tosylmethyl)oxazolidine (8a). 30% yield; white solid; IR (CH2Cl2) νmax
1
3064.1, 2963.9, 1597.1, 1350.3, 1318.9, 1163.7 cm–1; H-NMR (400 MHz, CDCl3) δ 7.82 (d,
J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5.13 (dd,
J = 8.8, 1.2 Hz, 1H), 3.90 (dd, J = 14.2, 1.4 Hz, 1H), 3.74 (dd, J = 9.4, 2.2 Hz, 1H), 3.34–3.44 (m, 2H),
3.07 (dd, J = 9.2, 6.0 Hz, 1H), 2.46 (s, 3H), 2.42 (s, 3H), 1.78–1.87 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H),
13
0.87 (d, J = 6.8 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 145.0, 136.6, 132.9, 130.1 , 129.9, 128.3,
128.1, 128.0, 86.7, 68.4, 64.4, 61.6, 31.3, 21.7, 19,4, 18.2; HRMS (ESI+) calcd for [C21H27NO5S2]+:
m/z 438.1403, found 438.1387.
(2S,4S)-4-Methyl-3-tosyl-2-(tosylmethyl)oxazolidine (8b). 68% yield; white oil; IR (CH2Cl2) νmax
3063.2, 2983.5, 1597.6, 1351.3, 1164.6 cm–1; 1H-NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.4 Hz, 2H),
7.56 (d, J = 13.6 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 5.17 (d, J = 9.2 Hz, 1H),
3.85 (d, J = 14.4 Hz, 1H), 3.63 (ddd, J = 11.1, 6.7, 2.7 Hz, 1H), 3.36–3.48 (m, 3H), 2.43 (s, 3H), 2.40
13
(s, 3H), 1.25 (d, J = 6.4 Hz, 3H); C-NMR (100 MHz, CDCl3) δ 145.0, 144.7, 136.7, 132.7, 130.1,
129.9, 128.3, 127.8, 86.8, 73, 61.6, 54.8, 21.7, 21.6, 20.7; HRMS (ESI+) calcd for [C19H23NO5S2]+:
m/z 410.1090, found 410.1094.
(2S,4S)-4-Benzyl-3-tosyl-2-(tosylmethyl)oxazolidine (8c). 65% yield; yellow oil; IR (CH2Cl2) νmax
1
3062.4, 3029.4, 2927.1, 1597.4, 1352.2, 1163.6 cm–1; H-NMR (400 MHz, CDCl3) δ 7.77 (d,
J = 8.4 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.15–7.37 (m, 9H), 5.18 (dd, J = 9.2, 1.6 Hz, 1H), 3.73–3.81
(m, 2H), 3.66 (dd, J = 9.4, 3.4 Hz, 1H), 3.22 (dd, J = 9.2, 6.4 Hz, 1H), 3.08 (dd, J = 14.6, 9.4 Hz, 1H),
13
3.02 (dd, J = 13.6, 3.2 Hz, 1H), 2.84 (dd, J = 13.4, 9.4 Hz, 1H), 2.46 (s, 3H), 2.42 (s, 3H); C-NMR
(100 MHz, CDCl3) δ 144.9, 136.7, 136.5, 132.8, 130.2, 129.8, 128.7, 128.3, 127.8, 127.0, 86.9, 69.5,
61.0, 59.8, 40.4, 21.7, 21.6; HRMS (ESI+) calcd for [C25H27NO5S2]+: m/z 486.1403, found 486.1403.
[(2S,4R)-3-Tosyl-2-(tosylmethyl)oxazolidin-4-yl]methanol (8d). 81% yield; white oil; IR (CH2Cl2) νmax
1
3532.6, 3063.3, 2928.6, 1597.3, 1351.3, 1164.0 cm–1; H-NMR (400 MHz, CDCl3) δ 7.78 (d,
J = 8.0 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5.24 (d,
J = 8.8 Hz, 1H), 3.76–3.83 (m, 2H), 3.53–3.65 (m, 4H), 3.38 (dd, J = 9.2, 6.4 Hz, 1H), 2.82 (s, 1H),
13
2.42 (s, 3H), 2.41 (s, 3H); C-NMR (100 MHz, CDCl3) δ 145.1, 145.0, 136.6, 132.4, 130.3, 13.2,
129.9, 129.8, 128.2, 127.9, 87.1, 68.0, 62.8, 60.9, 59.7, 21.7, 21.6; HRMS (ESI+) calcd for
[C19H23NO6S2]+: m/z 426.1040, found 426.1042.

Molecules 2011, 16
3822
(2S,3aS,7aS)-3-Tosyl-2-(tosylmethyl)octahydrobenzo[d]oxazole (8e). 37% yield; white oil; IR
1
(CH2Cl2) νmax 3056.0, 2942.9, 1597.4, 1352.8, 1161.4 cm–1; H-NMR (400 MHz, CDCl3) δ 7.82 (d,
J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.13 (dd,
J = 9.4, 1.4 Hz, 1H), 3.83 (dd, J = 14.8, 1.6 Hz, 1H), 3.54 (dd, J = 14.8, 9.6 Hz, 1H), 3.30 (ddd,
J = 11.8, 8.2, 2.0 Hz, 1H), 2.45 (s, 3H), 2.42 (s, 3H), 2.19–2.27 (m, 1H), 1.71–1.85 (m, 4H), 1.33–1.43
(m, 1H), 1.15–1.24 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 144.8, 136.8, 130.9, 130.3, 130.0, 128.4,
86.0, 80.8, 64.1, 60.7, 29.7, 29.5, 23.6, 23.2, 21.6; HRMS (ESI+) calcd for [C22H27NO5S2]+: m/z
450.1403, found 450.1406.
4. Conclusions
We have generated a chemical library of 60 unique oxazolidines, which will be tested for biological
activity. We have also expanded the scope of the possible pro-nucleophiles and electron-deficient
acetylenes that can be employed in mixed double-Michael reactions, thereby enabling the syntheses of
more-diverse oxazolidines.
Acknowledgments
This project was supported by grants (R01GM071779 and P41GM081282) from the U.S. National
Institutes of Health (NIH). We thank Greg Khitrov for mass spectrometric analyses. Funding for the
LCMS system was provided by the National Center for Research Resources (S10RR025631).
References and Notes
1. For review, see: Katritzky, A.R., Ed. Advances in Heterocyclic Chemistry; Academic Press:
London, UK, 2011; Volume 102 (and previous volumes).
2. For another review, see: Gribble, G.W., Joule, J.A., Eds. Progress in Heterocyclic Chemistry;
Elsevier: Oxford, UK, 2011; Volume 22 (and previous volumes).
3. Dolle, R.E.; Le Bourdonnec, B.; Worm, K.; Morales, G.A.; Thomas, C.J.; Zhang, W.
Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology.
J. Comb. Chem. 2010, 12, 765–806.
4. Terret, N.K. Combinatorial Chemistry; Oxford University Press: Oxford, UK, 1998.
5. Schreiber, S.L. Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery.
Science 2000, 287, 1964–1969.
6. Nielsen, T.E.; Schreiber, S.L. Towards the Optimal Screening Collection: A Synthesis Strategy.
Angew. Chem. Int. Ed. Engl. 2008, 47, 48–56.
7. Galloway, W.R.J.D.; Isidro-Llobet, A.; Spring, D.R. Diversity-oriented synthesis as a tool for the
discovery of novel biologically functional small molecules. Nat. Commun. 2010, 1, 80–92.
8. Schreiber, S.L., Kapoor, T.M., Wess, G., Eds. Chemical Biology: From Small Molecules to
Systems Biology and Drug Design; Wiley-VCH: Weinheim, Germany, 2008.
9. Strausberg, R.L.; Schreiber, S.L. From knowing to controlling: A path from genomics to drugs
using small molecule probes. Science 2003, 300, 294–295.
10. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727–730.

Molecules 2011, 16
3823
11. Zhu, X.; Lan, J.; Kwon, O. An Expedient Phosphine-Catalyzed [4 + 2] Annulation: Synthesis of
Highly Functionalized Tetrahydropyridiness. J. Am. Chem. Soc. 2003, 125, 4716–4717.
12. Zhu, X.; Henry, C.E.; Kwon, O. A highly diastereoselective synthesis of 3-carbethoxy-2,5-
disubstituted-3-pyrrolines by phosphine catalysis. Tetrahedron 2005, 61, 6276–6282.
13. Zhu, X.; Henry, C.E.; Wang, J.; Dudding, T.; Kwon, O. A Phosphine-Catalyzed Synthesis of 1,3-
Dioxan-4-ylidenes. Org. Lett. 2005, 7, 1387–1390.
14. Zhu, X.; Schaffner, A.; Li, R.C.; Kwon, O. Phosphine-Catalyzed Synthesis of 6-Substituted
2-Pyrones: Manifestation of E/Z-Isomerism in the Zwitterionic Intermediate. Org. Lett. 2005, 7,
2977–2980.
15. Castellano, S.; Fiji, H.D.G.; Kinderman, S.S.; Watanabe, M.; De Leon, P.; Tamanoi, F.; Kwon, O.
Small-Molecule Inhibitors of Protein Geranylgeranyltransferase Type I. J. Am. Chem. Soc. 2007,
129, 5843–5845.
16. Henry, C.E.; Kwon, O. Phosphine-Catalyzed Synthesis of Highly Functionalized Coumarins. Org.
Lett. 2007, 9, 3069–3072.
17. Tran, Y.S.; Kwon, O. Phosphine-Catalyzed [4 + 2] Annulation: Synthesis of Cyclohexenes. J. Am.
Chem. Soc. 2007, 129, 12632–12633.
18. Creech, G.S.; Kwon, O. Alcohol-Assisted Phosphine Catalysis: One-Step Synthesis of
Dihydropyrone from Aldehyde and Allenoate. Org. Lett. 2008, 10, 429–432.
19. Watanabe, M.; Fiji, H.D.G.; Guo, L.; Umetsu, A.; Kinderman, S.S.; Slamon, D.J.; Kwon, O.;
Tamanoi, F. Inhibitors of protein geranylgeranyltransferase-I and Rab geranylgeranyltransferase
identified from a library of allenoate derived compounds. J. Biol. Chem. 2008, 283, 9571–9579.
20. Creech, G.S.; Zhu, X.; Fonovic, B.; Dudding, T.; Kwon, O. Theory-Guided Design of Brønsted
Acid-Assisted Phosphine Catalysis: Synthesis of Dihydropyrones from Aldehydes and Allenoates
Tetrahedron 2008, 64, 6935–6942.
21. Lu, J.; Chan, L.; Fiji, H.D.G.; Dahl, R.; Kwon, O.; Tamanoi, F. In vivo anticancer effect of a novel
inhibitor of protein geranylgeranyltransferase I. Mol. Cancer Ther. 2009, 8, 1218–1226.
22. Guo, H.; Xu, Q.; Kwon, O. Phosphine-Promoted [3+3] Annulation of Aziridines with Allenoates:
A Facile Enrty into Highly Functionalized Tetrahydropyridines. J. Am. Chem. Soc. 2009, 131,
6318–6319.
23. Lu, K.; Kwon, O. Phosphine-catalyzed [4+2] Annulation: Synthesis of Ethyl 6-phenyl-1-tosyl-
1,2,5,6-tetrahydropyridine-3-carboxylate. Org. Synth. 2009, 86, 212–224.
24. Khong, S.N.; Tran, Y.S.; Kwon, O. Equilibria Between Vinylogous Ylides and Phosphonium
Dienolate Zwitterions: Vinylogous Wittig Olefination Versus Vinylogous Aldol-Type Reactions.
Tetrahedron 2010, 66, 4760–4768.
25. Wang, Z.; Castellano, S.; Kinderman, S.S.; Argueta, C.E.; Beshir, A.B.; Fenteany, G.; Kwon, O.
Diversity via a Branched Reaction Pathway: Generation of A Library of Sixteen Muticyclic
Scaffolds and Identification of Anti-Migratory Agents. Chem. Eur. J. 2011, 17, 649–654.
26. Andrews, I.P.; Kwon, O. Phosphine Catalyzed [3+2] Annulation: Synthesis of Ethyl 5-(tert-
Butyl)-2-phenyl-1-Tosyl-3-Pyrroline-3-Carboxylate. Org. Synth. 2011, 88, 138–151.
27. Choi, J.; Mouillesseauex, K.; Wang, Z.; Fiji, H.D.G.; Kinderman, S.S.; Otto, G.W.; Geisler, R.;
Kwon, O.; Chen, J.-N. Alplexone Targets the HMG-CoA Reductase Pathway and Differentially
Regulates Arteriovenous Angiogenesis. Development 2011, 138, 1173–1182.

Molecules 2011, 16
3824
28. Cruz, D.; Wang, Z.; Kibbie, J.; Modlin, R.; Kwon, O. Diversity through phosphine catalysis
identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven innate
immunity. Proc. Natl. Acad. Sci. USA 2011, 108, 6769–6774.
29. Martin, T.J.; Tran, Y.S.; Vakhshori, V.G.; Kwon, O. Phosphine-Catalyzed β′-Umpolung Addition
of Activated α-Alkyl Allenes. Org. Lett. 2011, DOI:10.1021/ol200697m.
30. Vardhineedi, S.; Barcan, G.A.; Kwon, O. Bisphosphine-Catalyzed Mixed Double-Michael
Reactions: Asymmetric Synthesis of Oxazolidines, Thiazolidines, and Pyrrolidines. J. Am. Chem.
Soc. 2007, 129, 12928–12929.
31. Vardhineedi, S.; Kwon, O. Diphosphine-Catalyzed Mixed Double-Michael Reaction: A Unified
Synthesis of Indolines, Dihydropyrrolopyridines, Benzimidazolines, Tetrahydroquinolines,
Tetrahydroisoquinolines, Dihydrobenzo-1,4-oxazines, and Dihydrobenzo-3,1-oxazines. Org. Lett.
2010, 12, 1084–1087.
32. White, D.A.; Baizer, M.M. Michael additions catalyzed by phosphines. An overlooked synthetic
method. Tetrahedron Lett. 1973, 14, 3597–3600.
33. Inanaga, J.; Baba, Y.; Hanamoto, T. Organic Synthesis with Trialkylphosphine Catalysts.
Conjugate Addition of Alcohols to α,β-Unsaturated Alkynic Acid Esters. Chem. Lett. 1993, 2,
241–244.
34. Grossman, R.B.; Pendharkar, D.S.; Patrick, B.O. [n + 1] Annulation Route to Highly Substituted
Cyclic Ketones with Pendent Ketone, Nitrile, and Ester Functionality. J. Org. Chem. 1999, 64,
7178–7183.
35. Grossan, R.B.; Comesse, S.; Rasne, R.M.; Hattori, K.; Delong, M.N. Phosphoramidites Are
Efficient, Green Organocatalysts for the Michael Reaction. Mechanistic Insights into the
Phosphorous-Catalyzed Michael Reaction of Alkynones and Implications for Asymmetric
Catalysis. J. Org. Chem. 2003, 68, 871–874.
36. Yavari, I.; Souri, S.; Sirouspour, M.; Djahaniani, H. Vinylphosphonium Salt Mediated Reaction
between Alkyl Propiolates and Aminophenols or Hydroxyphenols. Synthesis 2006, 3243–3249.
37. Dithianes can be formed through the double-Michael reaction of propane 1,3-dithiol in the
presence of bases (e.g., NaOMe, NaOEt, NBu4OH); see: Gaunt, M.J.; Sneddon, H.F.; Hewitt, P.R.;
Orsini, P.; Hook, D.F.; Ley, S.V. Development of β-keto 1,3-dithianes as versatile intermediates
for organic synthesis. Org. Bimol. Chem. 2003, 1, 15–16.
38. Scott, J.D.; Williams, R.M. Total Synthesis of (–)-Tetrazomine. Determination of the
Stereochemistry of Tetrazomine and the Synthesis and Biological Activity of tetrazomine
Analogues. J. Am. Chem. Soc. 2002, 124, 2951–2956.
39. Herberich, B.; Scott, J.D.; Williams, R.M. Synthesis of a netropsin conjugate of a water-soluble
epi-quinocarcin analogue: The importance of stereochemistry at nitrogen. Bioorg. Med. Chem.
2000, 8, 523–532.
40. Jacobsen, E.N., Pfaltz, A., Yamamoto, H., Eds. Comprehensive Asymmetric Catalysis I–III, 2nd
ed.; Springer: Berlin, Germany, 1999.
41. Ojima, I., Ed. Asymmetric Synthesis; VCH: New York, NY, USA, 2000.
42. Fache, F.; Schultz, E.; Tommasino, M.L.; Lemaire, M. Nitrogen-Containing Ligands for
Asymmetric Homogeneous and Heterogeneous Catalysis. Chem. Rev. 2000, 100, 2159–2232.
43. Paquette, L.A., Ed. Chiral Reagents for Asymmetric Synthesis; Wiley: Chichester, UK, 2003.

Molecules 2011, 16
3825
44. Seayad, J.; List, B. Asymmetric organocatalysis. Org. Biomol. Chem. 2005, 3, 719–724.
45. Wolf, C.; Xu, H. Asymmetric catalysis with chiral oxazolidine ligands. Chem. Commun. 2011, 47,
3339–3350.
46. Characterization of 1d: Choi, J.Y.; Borch, R.F. Highly Efficient Synthesis of Enantiomerically
Enriched 2-Hydroxymethylaziridines by Enzymatic Desymmetrization. Org. Lett. 2007, 9,
215–218.
47. Pei, Y.; Brade, K.; Brulé, E.; Hagber, L.; Lake, F.; Moberg, C. A General Method for the
Preparation of Chiral TREN Derivatives. Eur. J. Org. Chem. 2005, 2005, 2835–2840.
48. Berry, M.B.; Craig, D. A Convenient Method for the Preparation of Enantiomerically Pure
2-Substituted N-Tosylaziiridines. Synlett 1992, 41–44.
49. Wang, Z.; Cui, Y.-T.; Xu, Z.-B.; Qu, J. Hot Water-Promoted Ring-Opening of Epoxides and
Aziridines by Water and Other Nucleophiles. J. Org. Chem. 2008, 73, 2270–2274.
50. Yamashita, H. Metal(II) d-Tartrates Catalyzed Asymmetric Ring Opening of Oxiranes with
Various Nucleophiles. Bull. Chem. Soc. Jpn. 1988, 61, 1213–1220.
51. Schiffers, I.; Rantanen, T.; Schmidt, F.; Bergmans, W.; Zani, L.; Bolm, C. Resolution of Racemic
2-Aminocyclohexanol Derivatives and Their Application as Lifands in Asymmetric Catalysis.
J. Org. Chem. 2006, 71, 2320–2331.
52. Chen, P.C.; Wharton, R.E.; Patel, P.A.; Oyelere, A.K. Direct diazo-transfer reaction of β-lactam:
Synthesis and preliminary biological activities of 6-triazolylpenicillanic acids. Bioorg. Med.
Chem. 2007, 15, 7288–7300.
53. Calieno, G.; Fiorino, F.; Perissutti, E.; Severino, B.; Scolaro, D.; Gessi, S.; Cattabriga, E.;
Borea, P.A.; Santagada, V. A convenient synthesis by microwave heating and pharmacological
evaluation of novel benzoyltriazole and saccharine derivatives as 5-HT1A receptor ligands. Eur. J.
Pharm. Sci. 2002, 16, 15–28.
54. Chassaing, S.; Kueny-Stotz, M.; Isorez, G.; Brouillard, R. Rapid Preparation of 3-
Deoxyanthocyanidins and Novel Dicationic Derivatives: New Insight into an Old Procedure. Eur.
J. Org. Chem. 2007, 38, 2438–2448.
55. Maeda, Y.; Kakiuchi, N.; Matsumura, S.; Nishimura, T.; Kawamura, T.; Uemura, S.
Oxovanadium Complex-Catalyzed Aerobic Oxidation of Propargylic Alcohols. J. Org. Chem.
2002, 67, 6718–6724.
56. Ramachandran, P.V.; Rudd, M.T.; Reddy, M.V.R. Stereoselective synthesis of hex-2-(E)-en-4-yn-
1,6-dioates and E,Z-muconic acid diesters via organo-catalyzed self-coupling of propiolates.
Tetrahedron Lett. 2005, 46, 2547–2549.
57. Balas, L.; Jousseaume, B.; Langwost, B. Improved preparation of aliphatic propynoic esters.
Tetrahedron Lett. 1989, 30, 4525–526.
Sample Availability: Samples of compounds 3a–8e are available from the authors.
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).